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ABSTRACT 
 Parkinson Disease (PD) is the second most common neurodegenerative 
disorder, clinically characterized by severe motor impairment and pathologically 
characterized by progressive loss of the dopaminergic neurons of the substantia 
nigra pars compacta (SNpc) as well as the formation of cellular aggregate 
deposits called Lewy Bodies. While some advances have been made in 
understanding the molecular underpinnings of the disorder, the molecular 
implications of common genetic factors increasing risk for PD have not been 
adequately studied. First identified by GWA studies in 2009, the 
GAK/DGKQ/IDUA region on chromosome 4p16.3 shows significant genetic 
association to risk for PD, and the GAK protein has been shown to be associated 
with the primary component of Lewy Bodies, α-synuclein. In order to determine 
which gene in the 4p16.3 region may account for the genetic association to PD 
and to understand the molecular consequences of that association, post-mortem 
cortical brain tissue from 29 PD and 49 control patients was RNA-sequenced and 
differential exon usage in the context of disease and risk variant carrier status 
 viii 
was analyzed.  Exons in the 3’ region of GAK were found to be associated to 
case status, and notably exon 25 expression in GAK was associated with both 
case status and the risk variant. This exon was further observed to be associated 
to several genes previously shown to interact with GAK, including SNCA, which 
codes for α-synuclein. As a proxy for expression of the 3’ region of GAK, exon 25 
was assessed for genome-wide association, and genes showing association to 
the exon were involved in pathways related to synaptic transmission and 
neuronal function. In order to validate these findings, microarray analysis of 
primary rat cortical neurons in which GAK expression was reduced by shRNA 
transduction was performed. GAK expression in rat neurons was significantly 
inversely correlated to endogenous SNCA expression, and also exhibited 
association to pathways involved in synaptic transmission and mitochondrial 
function. Together, these findings suggest aberrant GAK expression related to 
genetic risk to be an important factor in the pathogenesis of PD through GAK’s 
influence on SNCA expression and through dysregulation of important neuronal 
pathways.  
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CHAPTER ONE – INTRODUCTION 
1. Parkinson Disease 
1.1. General Background 
 Parkinson Disease (OMIM 168600) is a progressive neurodegenerative 
disorder first described by Dr. James Parkinson of the British Royal College of 
Surgeons in 1817. In his publication An Essay on the Shaking Palsy, he 
described patients suffering from the disease as being afflicted with clinical motor 
symptoms including bradykinesia (slowness of movement), muscular rigidity, 
resting tremor, and postural instability1. Today, PD is recognized as the second 
most common neurodegenerative disease after Alzheimer Disease (OMIM 
104300) and affects approximately 1% of the population over the age of 50, with 
risk for onset increasing with age2. Current therapeutic approaches are designed 
to treat motor symptoms of the disease and include small molecule therapies 
(Levodopa, Monoamine Oxidase B inhibitors, Dopamine Agonists), and more 
invasive treatments (Deep-Brain Stimulation); however, therapies to slow or halt 
the progression of the disease remain elusive3.  
 Post-mortem pathological analysis of individuals suffering from PD reveals 
progressive neurodegeneration in several regions of the brain, beginning in the 
brain stem, and proceeding through the pons, midbrain, basal ganglia, and in 
some cases, the neocortex (Figure 1)4. In particular, a pathological hallmark of 
the disease is the loss of neuro-melanin containing dopaminergic neurons of the 
substantia nigra, pars compacta, with high correlation between degeneration of  
 2 
 
Figure 1. The Neuropathological Progression of PD. Lesions first appear in 
the brainstem, and then proceed through the pons and the midbrain wherein lies 
the substantia nigra. Next, cellular damage becomes evident in the basal ganglia, 
followed finally by involvement of the neocortex, including high order sensory 
association areas and prefrontal cortex, first order sensory and premotor cortex, 
and primary sensory and motor cortex. Adapted from Braak et al. 2003. 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
this specific region and severe symptomology5. At the microscopic level, a 
second pathologic hallmark of PD is formation of intracellular protein aggregate 
lesions found in the neurons present within afflicted brain regions; the spindle-like 
aggregates which are localized to cell processes are termed Lewy Neurites (LNs), 
whereas the lesions formed in the neuronal cell body are termed Lewy Bodies 
(LBs)4. These Lewy Bodies and Neurites are composed of many misfolded 
proteins, but are prominently characterized by the accumulation of the lipid-
binding, pre-synaptic protein α-synuclein (OMIM 163890).  
1.2. Molecular Dysregulation in Parkinson Disease 
 While the specific function of α-synuclein remains unclear, it has been 
observed to play a role in neurotransmitter release, vesicular trafficking/recycling, 
and in synaptic plasticity6-20. In sporadic PD, α-synuclein is proposed to first form 
small oligomers, which are hypothesized to be the toxic species affecting 
neuronal viability in the afflicted brain regions15,21-25. In an attempt to sequester 
the deadly oligomers, neurons isolate and convert these species into higher 
order aggregate fibrils that constitute the major components of LBs and LNs26-28 
and are hypothesized to be less toxic than the soluble oligomers.  
 Several molecular pathways have been described to be dysregulated in 
PD that can ultimately lead to the aggregation of α-synuclein protein. These 
dysfunctional pathways can lead to changes in the overall expression of α-
synuclein, the manner in which it is folded and processed, and the ability of the 
cell to degrade the protein. In particular, the molecular basis of one form of 
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familial PD is observed to be due to the aberrant multiplication of the gene 
encoding α-synuclein, SNCA, which causes increased mRNA expression and 
amounts of the protein overall29,30; still other forms of familial PD are caused by 
specific point mutations in SNCA that can lead to increased ability of the protein 
to aggregate21. Aberrant regulation of cell degradation and autophagic pathways 
responsible for normal clearance of α-synuclein has been proposed as a major 
contributor to α-synuclein aggregation and overall cellular dysfunction; in 
particular, disruption of the process of chaperone-mediated autophagy by 
oligomeric α-synuclein appears to play a major role in progression of the 
disease31, while breakdown of the autophagic process can hamper the clearance 
of α-synuclein oligomers and lead to greater neuronal toxicity32. 
1.3. Genetics of Parkinson Disease 
 While the underlying causes of both sporadic and familial Parkinson 
Disease are not well defined, a concerted effort has been made in the last 20 
years to understand the contribution that genetic heritability and variation may 
have in affecting the risk of the disease. As mentioned above, several mutations 
and multiplications have been identified in the SNCA gene, as well as the LRRK2 
gene, which can lead to monogenic autosomal-dominant forms of PD, but these 
variants are rare in the general population2,29,30,33,34. Genetic linkage studies in 
large sporadic and familial cohorts identified a number of loci linked to risk for PD 
or influencing onset age of the disease, but were often not able to identify 
specific genes or variants responsible for the linkage35-40. However, some genes 
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contained within these loci, including MAPT, were identified through candidate 
studies as containing SNPs with association to PD35,41. 
 Focused GWA studies of PD patient cohorts, whereby millions of variants 
can be tested for association to disease in an unbiased manner, has led to the 
identification of a number of SNPs contained within both genes with prior 
evidence for a relationship to PD etiology and genes with no prior evidence for 
association (Table 1). One such study performed by the Myers Lab at Boston 
University School of Medicine in collaboration with the Foroud Lab at Indiana 
University in 2009 identified an intronic SNP contained within a newly identified 
locus on chromosome 4p16.3 as being associated with risk for PD42. Upon 
further examination through targeted sequencing analysis, the region was shown 
to have several SNPs in high linkage disequilibrium with the risk SNP, and 
several of these SNPs occurred in the region encoding for the Cyclin G-
associated Kinase (GAK). 
 
2. Cyclin G-Associated Kinase 
2.1. Protein Structure and Function 
 The Cyclin G-associated Kinase (OMIM 602052) was first identified in a 
rat fibroblast cDNA library screen for binding partners to cyclin G, and was 
observed to have an N-terminal Serine/Threonine kinase domain similar in 
structure to that of the proteins Nek1, CDK2, Plk, and Tsk-1, and a C-terminal 
domain resembling the brain-specific protein Auxilin-143. Further analysis of the 
 6 
Table 1. Genome-wide Significant SNPs associated with PD. Genome-wide 
SNP data from 13,728 PD patients and 95,282 controls was meta-analyzed for 
association to PD risk. Twenty-six loci were identified as being associated to risk, 
with the threshold for genome-wide statistical significance set to a p-value of 
5x10-8. These SNPs were then validated for association in a separate set of 
5,353 PD cases and 5,551 controls, and 22 of the 26 loci were significantly 
associated to PD with a p-value of less than 0.05(Adapted from Nalls MA et al. 
2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Chr Position (bp) Gene Name(s)
Effect 
allele
Alternate 
allele
Effect allele 
frequency l2 Beta
Odds 
Ratio
Standard 
Error P l2 Beta
Odds 
Ratio
Standard 
Error P
rs35749011 1 155135036 GBA/SYT11 A G 0.017 0 0.566 1.762 0.057 6.09E-23 0 0.836 2.307 0.148 7.48E-09
rs823118 1 205723572 RAB7L1/NUCKS1 T C 0.559 55.7 0.119 1.126 0.016 1.36E-13 0 0.104 1.109 0.029 1.43E-04
rs10797576 1 232664611 SIPA1L2 T C 0.14 0 0.13 1.139 0.023 1.19E-08 26 0.104 1.11 0.039 3.38E-03
rs6430538 2 135539967 ACMSD/TMEM163 T C 0.43 0 -0.136 0.873 0.017 5.56E-15 47.9 -0.126 0.882 0.029 9.42E-06
rs1474055 2 169110394 STK39 T C 0.128 9.3 0.193 1.213 0.024 7.12E-16 54.4 0.198 1.218 0.042 1.07E-06
rs115185635 3 87520857 KRT8P25/APOOP2 C G 0.035 91 0.582 1.789 0.104 2.18E-08 30.4 -0.071 0.931 0.07 1.54E-01
rs12637471 3 182762437 MCCC1 A G 0.193 26.6 -0.17 0.844 0.021 3.32E-16 59 -0.179 0.836 0.036 3.72E-07
rs34311866 4 951947 TMEM175/GAK/DGKQ T C 0.809 52.4 -0.243 0.784 0.02 3.58E-33 55.4 -0.234 0.791 0.035 6.29E-12
rs11724635 4 15737101 BST1 A C 0.553 14.8 0.116 1.122 0.016 8.07E-13 20.6 0.129 1.138 0.028 2.73E-06
rs6812193 4 77198986 FAM47E/SCARB2 T C 0.364 29.5 -0.108 0.897 0.017 7.17E-11 10.7 -0.067 0.935 0.029 1.13E-02
rs356182 4 90626111 SNCA A G 0.633 48.5 -0.306 0.737 0.018 3.23E-67 34.4 -0.196 0.822 0.028 1.75E-12
rs9275326 6 32666660 HLA-DQB1 T C 0.094 2.1 -0.227 0.797 0.032 5.82E-13 0 -0.105 0.9 0.05 1.85E-02
rs199347 7 23293746 GPNMB A G 0.59 10 0.116 1.123 0.017 2.37E-12 26.6 0.07 1.072 0.029 7.66E-03
rs117896735 10 121536327 INPP5F A G 0.014 15.2 0.569 1.767 0.084 1.21E-11 0 0.339 1.404 0.111 1.10E-03
rs3793947 11 83544472 DLG2 A G 0.443 0 -0.092 0.912 0.017 2.59E-08 0 -0.024 0.976 0.028 2.01E-01
rs329648 11 133765367 LOC283174 T C 0.354 0 0.095 1.1 0.017 1.65E-08 48.5 0.114 1.121 0.029 4.38E-05
rs76904798 12 40614434 LRRK2 T C 0.143 0 0.157 1.17 0.022 1.33E-12 26.4 0.104 1.11 0.039 3.69E-03
rs11060180 12 123303586 CCDC62 A G 0.558 42.8 0.097 1.101 0.017 2.14E-08 0 0.108 1.114 0.028 7.26E-05
rs11158026 14 55348869 GCH1 T C 0.335 32.1 -0.118 0.889 0.018 7.13E-11 0 -0.054 0.948 0.03 3.87E-02
rs1555399 14 67984370 TMEM229B A T 0.468 97.2 -0.138 0.872 0.017 5.53E-16 0 -0.03 0.971 0.028 1.44E-01
rs2414739 15 61994134 VPS13C A G 0.734 29 0.108 1.114 0.018 4.13E-09 1.1 0.104 1.109 0.033 7.96E-04
rs14235 16 31121793 BCKDK/STX1B A G 0.381 25.5 0.09 1.094 0.016 3.89E-08 27.5 0.125 1.133 0.029 7.72E-06
rs17649553 17 43994648 MAPT T C 0.226 0 -0.261 0.771 0.021 4.86E-37 0 -0.269 0.764 0.035 7.03E-15
rs12456492 18 40673380 RIT2 A G 0.693 11.2 -0.1 0.905 0.017 5.12E-09 49.1 -0.105 0.9 0.03 2.16E-04
rs62120679 19 2363319 SPPL2B T C 0.314 47.1 0.132 1.141 0.022 2.53E-09 40.3 -0.002 0.999 0.034 4.82E-01
rs8118008 20 3168166 DDRGK1 A G 0.657 32.8 0.105 1.111 0.019 2.32E-08 0 0.107 1.113 0.029 1.18E-04
SNP Information Discovery phase (13,728 cases and 95,282 controls)
Replication phase (5,353 cases and 5,551 
controls)
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protein structure in both rat and human demonstrated that GAK contained many 
of the same features as that of its family member Auxilin-1, including the 
presence of a phosphatase/tensin domain (PTEN), clathrin-binding domain (CB), 
and J domain (Figure 2)44. 
 The protein is ubiquitously expressed and highly conserved, with its 
expression increasing during the G1 phase of the cell cycle; however, it does 
maintain a lower level constitutive expression pattern during other phases of 
mitosis and during G045. Intracellular immunostaining revealed GAK to be 
localized to both the cytoplasm, with evidence of association to the ER, TGN, 
and plasma membrane, as well as the nucleus, where it appeared to associate 
with cyclin G, p53, clathrin heavy chain (CHC), and protein phosphatase 2A 
(PP2A)47.  
 During mitosis, the protein plays a role in maintaining centrosomal integrity 
through proper spindle formation and is important in proper chromosomal 
condensation and alignment. Cells depleted of GAK become arrested at 
metaphase during the cell cycle, which is due to the activation of the spindle-
assembly checkpoint48. Specifically, GAK seems to be essential, in concert with 
clathrin, for proper microtubule outgrowth from the kinetochores on 
chromosomes, which allows for chromatin interactions during spindle assembly49. 
In MEFs where GAK is conditionally knocked out, centrosomes become over-
replicated as a result of DNA damage and aberrant mitogenic signaling50. Finally, 
GAK, through its phosphorylation of the B’γ subunit of PP2A, modulates the 
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Figure 2. Protein Domains of GAK, Homologous, and Orthologous Proteins. 
GAK shares a clathrin binding domain and J domain with its homolog Auxilin 1, 
as well as its orthologs C. elegans auxilin and yeast auxilin (Swa2p/Aux1p). It 
also shares a PTEN/tensin domain with Auxilin 1. The tetratricopeptide repeat  
(TPR) domain in the yeast ortholog is unique and serves as a scaffold for 
multiple proteins involved in mitosis. GAK uniquely maintains a kinase domain 
potentially important in protein sorting events. Dots on the proteins indicate AP2 
protein binding motifs46. 
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phosphatase activity of PP2A, which, in concert with cyclin G, is responsible for 
dephosphorylating MDM2 protein at specific residues, leading to a reduction of 
p53 levels after DNA damage response51. 
 While GAK’s roles during mitosis are important to its overall function, its 
primary responsibilities during G0 phase are essential for proper endocytosis and 
protein sorting. Specifically, GAK is required for proper dissociation of clathrin 
from clathrin-coated vesicles (CCVs) during endocytosis in non-neuronal cells44. 
Through its J domain, GAK interacts directly to stimulate the ATPase activity of 
Hsc70 protein, which is responsible for the dissociation of clathrin from 
endocytosed vesicles52. Moreover, GAK interacts directly with clathrin through its 
CB domain and, along with Hsc70, recruits clathrin to the plasma membrane 
during vesicle formation53,54. 
 Overexpression of the GAK protein in non-neuronal cells can lead to 
sequestration of clathrin and Hsc70 into aggregated cytosolic clusters, depleting 
the pool of clathrin from the plasma membrane and TGN and thus inhibiting 
endocytosis52,55. This effect is most likely attributable to GAK’s promotion of 
clathrin assembly in general and the inability of Hsc70, which is normally not 
highly expressed, to overcome and dissociate the assembled clathrin 
aggregates52. In contrast, when GAK is knocked down in cells, there is a 
dramatic decrease in the number of clathrin-coated pits (CCPs) and clathrin 
associated with the plasma membrane and TGN (leading to a decrease in 
endocytosis and intracellular trafficking), as well as a reduction in AP2 and AP1, 
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clathrin adaptor proteins, associated with these membranes53,56. This is most 
likely due to GAK’s role in assembly of these proteins on the plasma membrane 
and TGN. 
 In addition to its roles during endocytosis, GAK plays an important role in 
proper protein sorting at the plasma membrane and in the TGN. Specifically, 
GAK’s phosphorylation of the µ1 subunit of AP1 (TGN) and the µ2 subunit of 
AP2 (plasma membrane) proteins may be important in the recognition of specific 
sorting motifs on these protein subunits52,57. It has been observed that when 
phosphorylated by AAK1 (Adaptor-associated protein kinase 1, which has a 
kinase domain homologous to GAK), the µ2 subunit of AP2 is activated for 
recognition of YXXØ-type sorting signals, allowing for proper endocytosis of 
particular receptors, including Transferrin receptor56,58,59.  
 The functional implications of phosphorylation of the µ1 subunit of AP1 are 
unclear; however, GAK interacts directly with the γ subunit of AP1 through an 
“ear” domain, which allows it to associate with the TGN and results in the proper 
sorting of several key proteins from the TGN to the lysosome, including the acid 
hydrolase Cathepsin D60, a protease known to degrade α-synuclein61-64. Genetic 
knockdown of GAK results in dysfunctional sorting of this enzyme to the 
lysosome, which can be rescued by expression of an RNAi resistant form of GAK. 
Whether this interaction allows for other substrates in the TGN to be 
phosphorylated by GAK and mediate these sorting events remains unknown. A 
separate study identified GAK, as well as Hsc70 and AAK1, as interacting with 
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the lysosomal ATPase ATP13A2, which plays a role in maintaining proper 
lysosomal cation homeostasis65. A summary of GAK’s roles in endocytosis and 
protein sorting can be found in Figure 3.  
 Given the essential functions of GAK protein in mitosis, clathrin-mediated 
endocytosis, and protein trafficking, it is not surprising that total GAK knockout in 
mice is embryonic lethal66. Furthermore, GAK conditional knockout through a 
Cre-recombinase/loxP system in brain results in post-natal lethality as early as 
72 hours post-natal due to reduced proliferation of neuroprogenitor cells in the 
ventricular zone during embryonic development and as a result reduction of 
mature neurons in the cerebral cortex and hippocampus66. In a separate study, 
GAK knockdown during zebrafish embryogenesis was observed to cause 
neurodegeneration in several areas of the brain, including the hindbrain and 
some areas of the forebrain, due to dysfunctional Notch signaling in neural-
specific cells67. Together, these findings provide a role for GAK in brain 
development, and indicate that, although GAK’s homolog Auxilin-1 is expressed 
in the brain, it is not sufficient to recover reduction or loss of function of GAK in 
this system. 
2.2. GAK in Parkinson Disease 
 As mentioned above, a GWA study published in 2009 by the Myers Lab, in 
collaboration with the Foroud Lab, was the first to demonstrate an association of 
the GAK/DGKQ/IDUA region on chromosome 4p16.3 with PD42. Since then, this 
finding has been replicated in several different cohorts across many different 
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Figure 3. Functions of GAK During Clathrin-Mediated Endocytosis and 
Protein Sorting. A. After activation, receptors are often endocytosed as a 
negative feedback mechanism to prevent their continued signaling. During the 
nucleating stage of vesicle formation at the plasma membrane and TGN, GAK 
and Hsc70 recruit clathrin and adaptor proteins (including AP2 and 1, 
respectively). GAK also recruits and interacts with Dynamin during invagination 
and constriction. Upon vesicle budding, GAK stimulates the ATPase of Hsc70 to 
dissociate clathrin from the vesicle, and then these proteins chaperone clathrin 
back to the membranes to assemble new vesicles. B. Through its interaction with 
AP1 in the TGN and AP2 at the plasma membrane, GAK enables the sorting of 
particular proteins into CCPs to be endocytosed or trafficked to other organelles, 
(for example, Cathepsin D to the lysosome). 
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ethnic backgrounds68-78. To better elucidate the potential function of this variant 
in the context of PD, the Myers lab performed a Gene Expression Microarray 
study on mRNA isolated from Brodmann Area Nine of 29 Control and 33 PD 
post-mortem brains to determine if there was a relationship between the GWA 
risk SNP rs1564282 and expression probes for GAK, SNCA, or CTSD. The risk 
SNP was significantly associated with higher levels of SNCA in PD and Control 
after adjustment for multiple comparisons, while showing nominal association 
with lower levels of a probe covering Refseq exon 28 of GAK78. Relationships 
between the probes were also assessed; expression of a probe spanning Refseq 
exon 26 of GAK showed a significant positive correlation with expression of a 
probe for CTSD. 
 In order to elucidate a functional relationship between GAK and α-
synuclein, GAK was knocked down and α-synuclein cDNA was over-expressed 
via transient transfection techniques in Human Embryonic Kidney (HEK) 293 
cells, which resulted in a decrease in cell viability and an increase in total α-
synuclein protein levels78. Additionally, knockdown of GAK and over-expression 
of A53T-α-synuclein (which retains the mutation encoding for an Alanine to 
Threonine substitution at amino acid 53) via viral transduction in rat midbrain 
neuronal cultures resulted in decreased Tyrosine Hydroxylase-positive (TH+) 
dopaminergic cells as determined by immunofluorescence78. As mentioned 
above, GAK also demonstrates an interaction as mentioned with ATP13A2, a 
gene known to have genetic association with risk of PD; however, the role this 
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interaction might play in α-synuclein-mediated toxicity was not accessed65. More 
recently, GAK has been shown in vitro and in vivo to directly interact with Rab7L1 
and LRRK2, a heavily implicated protein in the context of PD, to form a complex 
responsible for clearance of Golgi-derived vesicles to the lysosome79. These 
findings indicate that GAK and α-synuclein may interact with one another to 
produce a pathogenic result that mirrors the etiology of Parkinson Disease. 
 Recently, two groups reported mutations in separate families mapping to 
the GAK homolog Auxilin-1 (encoded by the gene DNAJC6), which led to onset 
of early juvenile parkinsonism80,81. In one case, the SNP carried by the two 
patients causes a mis-splicing event that results in non-sense mediated decay of 
the mRNA transcripts81, while in the other, a premature termination signal caused 
by the SNP results in reduction of the mRNA size by about 20% and thus decay 
of the species80. While the mutations in DNAJC6 are rare, they demonstrate the 
importance of functional endocytotic and lysosomal pathways in the brain in 
which both GAK and Auxilin-1 play a role as it relates to PD and parkinsonisms. 
 
3. Hypothesis and Specific Aims 
 As the percentage of the elderly and those suffering from Parkinson 
Disease increases in the coming decades, the need for novel therapeutics 
targeting universal pathways to treat this complex disorder will become 
imperative. While genetic association studies link the GAK locus to risk for 
Parkinson Disease, the effect this association exerts on expression signatures in 
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human brain remains unclear. Furthermore, it appears that loss of GAK 
expression results in increased cell death and α-synuclein burden in the 
presence of over-expressed SNCA; however, the dysfunctional pathways leading 
to these phenotypes remain elusive. As GAK function has not been adequately 
studied in the brain and neurons in these contexts previously, the following work 
promises to address some of the questions surrounding GAK and its role in PD 
etiology. We hypothesize that decreased expression of GAK leads to increased 
synuclein-mediated neurotoxicity due to changes in the pathways in which GAK 
functions. In order to investigate this hypothesis, the following specific aims were 
devised and executed. 
 
3.1. Specific Aim 1: Investigate the Association of GAK Expression to the 
PD Risk SNP rs1564282 and to SNCA Expression. Based on previous 
experimental evidence, this aim assessed which specific exons in GAK are 
associated with the PD risk SNP and whether these exons have any relationship 
to SNCA expression in human brain samples. It also evaluated whether changes 
in GAK expression in vitro affect the expression of SNCA and genes associated 
with SNCA. 
 
3.2. Specific Aim 2: Analyze the Genome-wide Exon Expression Data and 
Genome-wide Microarray Expression for Novel Association to GAK 
Expression. This aim investigated novel genetic associations to GAK expression 
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in the context of PD in post-mortem brain tissue and in primary cortical neurons 
to evaluate previously unexplored pathways that GAK regulates or in which GAK 
participates. 
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Chapter Two – Materials and Methods 
1. Materials 
1.1. Brains Studied 
 Cryo-preserved post-mortem Brodmann Area 9 prefrontal brain tissue 
from PD cases with no extensive evidence of AD pathology and from 
neuropathologically-confirmed controls was acquired from three different brain 
banks: the Harvard Brain Tissue Resource Center at McLean Hospital (Belmont, 
Massachusetts), the Human Brain and Spinal Fluid Resource Center VA West 
Los Angeles Healthcare Center (Los Angeles, California) and Banner Sun Health 
Research Institute (Sun City, Arizona). The tissue was sectioned at each facility 
prior to arrival at BU, and an approximately 2.0g un-mounted block of tissue 
containing both gray and white matter was obtained. All tissue samples were 
stored at -80°C prior to being used. A description of the samples studied can be 
found in Table 2.  
 
2. Methods 
2.1 RNA-sequencing 
2.1.1. Total RNA Preparation from Human Tissue and Quality Control 
 During dissection, each tissue sample block was placed on glass cover-
slips, which were kept on a glass-plate under which was kept a frozen block 
surrounded by dry ice. A feather surgical blade was used to scrape 
approximately 0.1g of tissue from the grey matter of the tissue block and this  
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Table 2. Descriptive Characteristics of Brain Samples Studied. Brain bank 
from which tissue was obtained is listed in column two and the samples’ 
associated Brain Bank ID is listed in column 3. Age of Onset data is not 
applicable (N/A) for controls and was not available for some of the PD samples. 
Post-mortem interval (PMI) is given in hours, and Age at Death and Onset are 
given in years. 
  
BU 
Brain 
ID 
Brain 
Bank 
Brain 
Bank ID 
Case 
Status 
Age 
at 
Onset 
Age 
at 
Death 
PMI rs1564282 Genotype 
C_0002 Sun Health 04-08 Control N/A 73 2 CC 
C_0003 Sun Health 05-10 Control N/A 91 2 CC 
C_0004 Sun Health 05-36 Control N/A 82 2 CC 
C_0005 Sun Health 07-04 Control N/A 97 2 CT 
C_0006 Sun Health 07-28 Control N/A 86 5 CC 
C_0008 Sun Health 07-72 Control N/A 91 2 CC 
C_0009 Sun Health 97-02 Control N/A 81 3 CC 
C_0010 Sun Health 97-10 Control N/A 79 2 CC 
C_0011 Sun Health 98-27 Control N/A 63 2 CC 
C_0012 McLean B3688 Control N/A 66 19 CC 
C_0013 McLean B3732 Control N/A 69 15 CT 
C_0014 McLean B5074 Control N/A 79 21 TT 
C_0015 McLean B5392 Control N/A 61 10 CC 
C_0016 McLean B6092 Control N/A 58 20 CC 
C_0017 McLean B6096 Control N/A 70 21 CC 
C_0018 McLean B6124 Control N/A 66 17 CT 
C_0019 McLean B6152 Control N/A 73 19 CC 
C_0020 McLean B6200 Control N/A 60 24 CC 
C_0021 McLean B6207 Control N/A 76 26 CC 
C_0022 McLean B6213 Control N/A 61 17 CC 
C_0023 McLean B6225 Control N/A 62 18 CC 
C_0024 McLean B6341 Control N/A 69 26 CC 
C_0025 McLean B6356 Control N/A 61 25 CT 
C_0026 McLean B7012 Control N/A 88 11 CC 
C_0029 LA HSB3848 Control N/A 93 13 CC 
C_0031 McLean B6023 Control N/A 53 24 CC 
C_0032 McLean B6034 Control N/A 57 24 CT 
C_0033 McLean B6077 Control N/A 43 15 CC 
C_0035 McLean B6661 Control N/A 46 21 CC 
C_0036 McLean B4735 Control N/A 40 17 CC 
 19 
BU 
Brain 
ID 
Brain 
Bank 
Brain 
Bank ID 
Case 
Status 
Age 
at 
Onset 
Age 
at 
Death 
PMI rs1564282 Genotype 
C_0037 McLean B6018 Control N/A 44 28 TT 
C_0038 McLean B6030 Control N/A 57 20 CC 
C_0039 McLean B6326 Control N/A 80 15 CT 
C_0050 Sun Health 95-40 Control N/A 74 2 CC 
C_0053 Sun Health 96-38 Control N/A 69 2 CC 
C_0060 Sun Health 97-14 Control N/A 76 2 CC 
C_0061 Sun Health 97-17 Control N/A 78 3 CC 
C_0062 Sun Health 97-19 Control N/A 87 2 CT 
C_0065 Sun Health 99-14 Control N/A 86 2 CC 
C_0069 McLean B4751 Control N/A 54 24 CC 
C_0070 McLean B5847 Control N/A 68 19 CC 
C_0071 McLean B5998 Control N/A 106 21 CC 
C_0075 McLean B6087 Control N/A 52 23 CC 
C_0076 McLean B6104 Control N/A 46 30 CT 
C_0077 McLean B6162 Control N/A 36 21 CC 
C_0081 McLean B6260 Control N/A 55 26 CC 
C_0082 McLean B6289 Control N/A 57 18 CC 
C_0083 McLean B6314 Control N/A 66 32 CT 
C_0087 McLean B7010 Control N/A 64 19 CT 
P_0003 Sun Health 03-08 PD 72 74 3 CC 
P_0006 Sun Health 04-17 PD N/A 83 2 CC 
P_0012 Sun Health 94-05 PD 69 80 2 TT 
P_0013 Sun Health 94-31 PD 79 83 2 CT 
P_0014 Sun Health 95-14 PD 55 80 2 CC 
P_0015 Sun Health 95-19 PD 80 84 2 CC 
P_0016 Sun Health 96-36 PD 85 88 2 CT 
P_0018 Sun Health 98-24 PD 73 81 2 CC 
P_0019 Sun Health 98-29 PD 73 77 4 CC 
P_0020 Sun Health 99-08 PD 59 64 4 CT 
P_0021 Sun Health 99-63 PD N/A 85 3 CC 
P_0022 McLean B4954 PD N/A 94 9 CC 
P_0023 McLean B4994 PD 60 80 27 CT 
P_0026 McLean B5731 PD 65 85 16 CC 
P_0027 McLean B6444 PD N/A 75 7 CC 
P_0028 McLean B6900 PD N/A 74 15 CT 
P_0029 McLean B6903 PD 72 89 31 CC 
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BU 
Brain 
ID 
Brain 
Bank 
Brain 
Bank ID 
Case 
Status 
Age 
at 
Onset 
Age 
at 
Death 
PMI rs1564282 Genotype 
P_0030 McLean B6976 PD 55 66 11 CC 
P_0031 McLean B7029 PD N/A 65 8 CT 
P_0033 LA HSB3856 PD N/A 85 19 CC 
P_0034 Sun Health 00-09 PD 49 64 4 CC 
P_0063 Sun Health 98-38 PD 53 64 1 CC 
P_0126 McLean B6045 PD 61 75 30 CC 
P_0130 McLean B6425 PD 62 68 18 CT 
P_0132 McLean B6446 PD 80 95 16 CT 
P_0133 McLean B6479 PD 66 74 23 CT 
P_0134 McLean B6547 PD 63 68 23 CC 
P_0135 McLean B6623 PD 66 79 12 CC 
P_0136 McLean B6713 PD N/A 70 25 CC 
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sample was placed in a 1.5mL Eppendorf tube. The tissue was then lysed using 
750µL of Qiazol Lysis Reagent (Qiagen, Hilden Germany) and homogenized with 
a motorized pestle for two minutes at room temperature (RT). Total RNA was 
then extracted from the homogenate using the Qiagen miRNeasy Mini Kit 
following the standard protocol from the manufacturer. Briefly, the RNA was 
separated from the DNA and protein using chloroform, followed by addition of 
ethanol to provide the conditions for proper binding of the RNA to the spin 
column membrane. After several washes, the RNA was eluted with 40µL RNase-
free water into a fresh Eppendorf tube and stored at -80°C. 
 Total RNA was quantified on a Biotek (Winooski, Vermont) Synergy H1 
Hybrid Plate reader using a Take3 Micro-Volume Plate. A 260nm/280nm 
absorbance reading was taken for all samples using this plate to determine purity 
of RNA extracted (with 260/280 values between 2 and 2.1 considered highly 
pure), and concentration was calculated based on the 260nm OD (optical 
density). RNA quality for each sample was assessed with the Agilent 
Technologies (Santa Clara, California) 2100 Bioanalyzer using standard protocol 
as specified by the manufacturer. Briefly, 1µL of each sample (at a concentration 
of 4ng/µL) was loaded into an RNA 6000 Nano Chip along with a standard RNA 
ladder and run on the instrument. An electropherogram was obtained for each 
sample and the RNA integrity Number (RIN) was calculated based on the ratio of 
the area under the densitometry peaks produced by the 18S and 28S eukaryotic 
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ribosomal subunits. Samples with RINs greater than 6.0 were used in the studies 
and samples failing to reach this threshold were re-extracted. 
2.1.2. Library Creation from Human Cortical RNA 
 Libraries of cDNA derived from poly-adenylated mRNA were created at 
the Tufts University Core Facility (Boston MA, http://tucf-genomics.tufts.edu/) 
from the total RNA for each sample using the Illumina (San Diego, California) 
TruSeq mRNA Sample Preparation Kit. Briefly, mRNA was separated from 
approximately 1µg of total mRNA input using poly-thymidylic acid conjugated to 
magnetic beads and then chemically fragmented at elevated temperatures. Next, 
cDNA was synthesized from these fragments using random hexamers, upon 
which an adaptor was ligated which served as the template for amplification 
primers during PCR as well as contained a specific index barcode specific to the 
sample. Finally the libraries were purified, assessed on the Agilent 2100 
Bioanalyzer using a DNA 1000 Chip (standard manufacturer’s protocol followed), 
and pooled so that three different samples would be sequenced per flowcell lane 
on a high-throughput sequencer. 
2.1.3. mRNA Sequencing 
 Pooled cDNA libraries derived from PD and control cortical tissue were 
sequenced on an Illumina HiSeq 2000 System at the Tufts University Core 
Facility. Sequence reads were specified to be paired-end (sequenced from both 
ends of the cDNA fragment) and approximately 100 bp long. The sequence data 
was demultiplexed and output to FASTQ files for each sample using the Illumina 
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Consensus Assessment of Sequence and Variation (CASAVA) pipeline (with two 
files generated per file corresponding to each end read), which were then used 
for subsequent analysis. 
2.1.4. Data Alignment and Quality Control Analysis 
 Sequence data was aligned to the UCSC human reference genome 19 
using the spliced read mapper Tophat version 2.0.682, which first aligns short 
reads using the high-throughput aligner Bowtie version 2.1.083, followed by 
analysis of the mapped results for the presence of splice junctions. Read inner 
distance (the length of unsequenced fragment cDNA between paired reads) and 
standard deviation of the inner distance were estimated to be 50 bp each (the --
mate-inner-dist option and --mate-std-dev option, respectively). The number of 
mismatches to the genome allowed for each read was 3 (--read-mismatches 
option) while the number of splice mismatches allowed was 1 (--splice-
mismatches option). Finally, the read edit distance (--read-edit-dist option) was 
set to 3, and the maximum number of alignments to the genome for each read (--
max-multihits option) was set to 20. All other alignment options were set to 
default. 
 The output BAM files from the alignment were then used to perform quality 
control analysis using the RSeQC python package84. This package assesses 
reads mapping statistics (through the bam_stat.py script), including the total 
number of aligned reads from overall total reads, how many of those reads have 
a matched pair for a particular fragment, and how many of the reads map to 
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splice junctions versus non-spliced sequences. It can also assess the gene body 
coverage (geneBody_coverage.py), GC content of each read (read_GC.py), and 
read quality according to each read’s requisite Phred score (read_quality.py) 
among other assessment options. None of the samples were assessed as 
outliers among the group as evaluated by RSeQC, and so all were carried 
forward in the analysis.  
2.1.5. mRNA Exon Abundance Quantification 
 The alignment BAM files for each sample were first sorted by read names 
and had reads extracted from the binary BAM format to the SAM format using 
SAMtools85. Next, an annotation GFF file containing collapsed exon/partial exon 
counting bins with specific boundaries for all known human transcripts was 
created from the GENCODE version 14 annotation GTF file 
(http://www.gencodegenes.org/releases) using the python script 
dexseq_prepare_annotation.py found in the HTSeq version 0.5.3p9 package 
(http://www-huber.embl.de/users/anders/HTSeq); this new exon annotation file, 
along with the sorted SAM files for each sample, were used to count paired reads 
in each exon counting bin using the dexseq_count.py script found in HTSeq. 
2.1.6. Exon Normalization using DEXSeq 
 The exon raw read counts for each sample were next normalized using 
the R (http://www.R-project.org) package DEXSeq version 1.6.086. The function 
estimateSizeFactors was used to obtain normalization factors for each sample 
with respect to the other samples and to normalize the exon counts by this factor. 
 25 
These normalized counts were then used for both locus specific and genome-
wide differential expression analysis using functions contained in the R package 
MASS87. 
2.1.7. Gene Specific Exon Analysis 
 Gene-specific normalized exon counts were extracted from the exon count 
set object generated by DEXSeq for several regions of the genome. These 
genes and their exons were selected based on their proximity to PD risk SNP 
rs1564282 (which include GAK, TMEM175, DGKQ, SLC26A1, and IDUA) or 
based on a purported functional association to the GAK (Table 3) or SNCA 
(Table 4) gene as determined by the functional protein association network 
database STRING (http://string-db.org). 
 The exons contained in GAK were assessed for their differential usage in 
all cases as compared to all controls (unadjusted) using a Generalized Linear 
Model (GLM) assuming a negative binomial distribution of the data. This GLM 
function implemented in the R MASS package estimated the dispersion 
parameter for the data based on a set number of iterations and a given initial 
starting theta value, which was set to the default of 1. All other options for the 
function were left to the default. The resulting p-values for this analysis and all 
subsequent analyses were adjusted for multiple comparisons using the false 
discovery rate (FDR) control as described by Benjamini and Hochberg88, with a 
threshold cutoff of 0.05. 
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Table 3. GAK-associated Candidate Genes’ Exons for Targeted Analyses. A 
confidence score greater than 0.40 was chosen as a minimum threshold for 
inclusion. 
 
 
 
 
 
 
 
 
Ensemble ID Gene Name Number of Exons
Confidence 
Score
ENSG00000169083 AR 16 0.85
ENSG00000137203 TFAP2A 46 0.8
ENSG00000109971 HSPA8 74 0.692
ENSG00000113328 CCNG1 42 0.683
ENSG00000161203 AP2M1 55 0.669
ENSG00000129354 AP1M2 33 0.666
ENSG00000141367 CLTC 62 0.664
ENSG00000164885 CDK5 22 0.646
ENSG00000072958 AP1M1 46 0.635
ENSG00000005339 CREBBP 54 0.619
ENSG00000130787 HIP1R 55 0.58
ENSG00000175166 PSMD2 69 0.577
ENSG00000065609 SNAP91 82 0.566
ENSG00000171094 ALK 39 0.525
ENSG00000127946 HIP1 41 0.488
ENSG00000138768 USO1 43 0.474
ENSG00000156006 NAT2 5 0.462
ENSG00000133961 NUMB 65 0.461
ENSG00000112902 SEMA5A 28 0.424
ENSG00000079805 DNM2 72 0.42
ENSG00000105245 NUMBL 12 0.42
ENSG00000145335 SNCA 26 0.412
ENSG00000153234 NR4A2 30 0.4
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Table 4. SNCA-associated Candidate Genes’ Exons for Targeted Analyses. 
The top 40 genes were selected for inclusion based on their Confidence Score 
ranking. 
 
 
Ensemble ID Gene Name Number of Exons
Confidence 
Score
ENSG00000064692 SNCAIP 50 0.999
ENSG00000150991 UBC 51 0.999
ENSG00000185345 PARK2 17 0.998
ENSG00000142319 SLC6A3 25 0.989
ENSG00000103266 STUB1 38 0.986
ENSG00000010810 FYN 82 0.983
ENSG00000198873 GRK5 21 0.983
ENSG00000002330 BAD 18 0.983
ENSG00000116288 PARK7 28 0.983
ENSG00000188906 LRRK2 66 0.981
ENSG00000181788 SIAH2 9 0.979
ENSG00000142192 APP 49 0.971
ENSG00000167755 KLK6 12 0.969
ENSG00000136827 TOR1A 12 0.959
ENSG00000075651 PLD1 63 0.959
ENSG00000254087 LYN 20 0.959
ENSG00000165025 SYK 19 0.959
ENSG00000000938 FGR 29 0.959
ENSG00000196470 SIAH1 23 0.953
ENSG00000186868 MAPT 33 0.943
ENSG00000129219 PLD2 61 0.942
ENSG00000154277 UCHL1 35 0.932
ENSG00000121351 IAPP 13 0.921
ENSG00000185651 UBE2L3 10 0.914
ENSG00000182866 LCK 42 0.914
ENSG00000136156 ITM2B 11 0.908
ENSG00000171560 FGA 7 0.907
ENSG00000166710 B2M 36 0.906
ENSG00000118137 APOA1 11 0.905
ENSG00000163932 PRKCD 29 0.905
ENSG00000118271 TTR 7 0.905
ENSG00000148180 GSN 66 0.901
ENSG00000109205 ODAM 18 0.9
ENSG00000124233 SEMG1 6 0.9
ENSG00000112640 PPP2R5D 35 0.899
ENSG00000120708 TGFBI 58 0.899
ENSG00000101439 CST3 9 0.899
ENSG00000175206 NPPA 5 0.899
ENSG00000101336 HCK 25 0.899
ENSG00000142798 HSPG2 131 0.899
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 A stratified analysis was also performed on the data, first stratifying by 
case status and evaluating the association to the risk SNP rs1564282, and then 
stratifying by the risk SNP (separating groups by carriers and non-carriers) and 
assessing the association to case status. A multivariable GLM was then used to 
model the association of case status and the risk SNP (in an additive genetic 
model). Next, a Pearson correlation analysis was performed between the exons 
in GAK to assess the correspondence in expression among them. Additionally, a 
multivariable GLM analysis was performed together on the exons in GAK, DGKQ, 
TMEM175, SLC26A1, and IDUA to assess whether exons contained in these 
genes are associated to the risk SNP or case status. Finally, to assess the 
association of GAK expression to the expression of exons in genes purported to 
have a functional relationship to GAK or SNCA by STRING, GLM analysis was 
performed, modeling the association of GAK exon 25 (by DEXSeq annotation) to 
the expression of the exons in those other genes while controlling for case status, 
age at death, and PMI.  
2.1.8. Genome-wide Exon Association to GAK Exon 25 Analysis 
 The expression of GAK exon 25 was next assessed for genome-wide 
exon association using the GLM function in MASS after filtering exons with zero 
counts across all samples, adjusting for case status, age, and PMI. All resulting 
p-values were FDR adjusted for multiple comparisons, with a significance 
threshold set at 0.05. Those genes with greater than 50% of their exons showing 
significant association to GAK exon 25 expression after FDR adjustment were 
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used for functional annotation using the Database for Annotation, Visualization 
and Integrated Discovery (DAVID)89,90 and for pathway and network analysis 
using Integrated Pathway Analysis (IPA) (Ingenuity Systems, 
www.ingenuity.com). For the DAVID analysis, Ensembl gene ID’s were used as 
input for the annotation, while for IPA analysis, the gene ID as well as the 
association results for the most significant exon contained in that gene (by 
adjusted p-value) were used as input. These genes were then carried forward to 
comparative analyses with microarray data generated as described in Section 
2.6. 
2.2. Expression Plasmids and Cloning 
2.2.1. Plasmid Constructs 
 The pHAGE-2 dual promoter lentivirus backbone vector and lentiviral 
packaging vectors tat, rev, hgpm2, and vsv-g were generous gifts from the 
Mostoslavsky Lab at Boston University School of Medicine (Boston, MA). The 
pHAGE-2 vector contained the ZsGreen fluorescent protein driven by the human 
EF1-α promoter (and flanked by NotI and BamHI restriction sites) as well as the 
dTomato fluorescent protein driven by an IRES. Four lentiviral shRNA plasmids 
containing different 29-mer sequences targeting the rat GAK gene and driven by 
the human U6 promoter (Catalog number TL711161) were purchased from 
Origene Technologies (Rockville, Maryland). After testing for knockdown 
efficiency in PC-12 cells by transfection, shRNA construct B, which targets 
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RefSeq Exon 5 in GAK with the following 29-mer sequence, was used for all 
lentiviral-mediated knockdown experiments:  
5’-CTCTATCCTGCGACAGCATTCTGAAGATC-3’. 
 A pHAGE-2 vector expressing human Wild-type (WT) α-synuclein cDNA in 
place of ZsGreen was cloned using the pHAGE-2 vector described above. Briefly, 
α-synuclein cDNA was first cloned into the pCR2.1-TOPO vector (Life 
Technologies, Carlsbad CA) using the TOPO TA Cloning Kit provided following 
the manufacturer’s protocol and these sense and antisense primers (Integrated 
DNA Technologies, Coralville IA): 
Syn_NotI_Kozak_F: 
5’-ACGCAGCGGCCGCCACCATGGATGTATTC-3’ 
Asynuclein_R: 
5’-ACGCAACATCTTTAGGCTTCAGGTTCGTA-3’ 
These primers incorporated a Kozak sequence and new NotI/BglII restriction 
enzyme sites used for excision. Once positive clones of pCR2.1 containing α-
synuclein were obtained, the pHAGE-2 vector was cut using NotI and BamHI 
restriction enzymes to excise ZsGreen, while the pCR2.1 vector containing the α-
synuclein PCR product was cut using NotI and BglII enzymes (because BamHI 
and BglII have similar sticky ends, they would be ligated to each other). The cut 
vector and insert were then ligated together, transformed into bacteria, and 
purified using Mini/Midiprep kits to give the pHAGE-2-EF1-α-WT-α-synuclein-
IRES-dTomato vector. 
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2.2.2. Cloning PCR 
 This protocol was used for the PCR in the cloning process. Template 
cDNA was PCR amplified using the AmpliTaq Gold 360 Polymerase Kit (Life 
Technologies) and reaction mix consisted of 5µL of the 10x 360 Buffer, 4µL of 
25mM Magnesium Chloride, 1µL 360 GC Enhancer, 1µL AmpliTaq 360 
Polymerase, 4µL of 200µM dNTP mix, 0.2mM of each primer, 20ng of the cDNA 
template, and PCR-grade water to a total volume of 50µL. The PCR conditions 
used included an initial denaturation step for 10 minutes at 95°C, followed by 30 
cycles of denaturing (30 seconds at 95°C), annealing (30 seconds at 60°C), and 
extension (30 seconds at 72°C), and finalized with a 7 minute extension at 72°C. 
2.2.3. Restriction Enzyme Digestion 
 Restriction digest was used to cut out cDNA inserts from plasmids during 
subcloning. Restriction enzymes purchased from New England BioLabs (NEB) 
included NotI, BamHI, and BglII. To perform double digest with two different 
enzymes, 1µg of plasmid DNA was cut with one enzyme first in its specified 
buffer according to manufacturer’s instruction at 37°C for 2 hours, after which the 
second enzyme was added with its buffer and incubated at 37°C overnight. In 
order to determine the order of enzymes used, the first enzyme used had buffer 
with lower salt concentration than the second enzyme used.  
2.2.4. DNA Agarose Gel Electrophoresis 
 Gel Electrophoresis was used to purify PCR products and products of 
restriction enzyme digestion. Using Agarose-LE (Ambion/Life Technologies) and 
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1x TBE (8.9mM Tris Base, 8.9mM Boric Acid, 0.2mM EDTA), a 1% (w/v) solution 
was made, which was then heated in a microwave until the solids dissolved, 
infused with 0.5mg/µL of Ethidium Bromide to ensure DNA visualization, and 
then poured into a gel casting tray with a well comb in place. Upon cooling and 
hardening, 20µL of the sample, along with 4µL of 6x Loading Buffer (0.25% 
Bromophenol Blue, 30% glycerol) was loaded alongside a 1 kb DNA ladder 
(Promega, Madison WI) to allow for determination of molecular weight. A 100 V 
current was passed through the gel for 40 minutes to allow for separation, and 
the gel was then visualized under a UV lamp in order to view electrophoresed 
bands. 
2.2.5. DNA Gel Extraction 
 This protocol was used to extract the purified DNA product from the 
agarose gel. The desired DNA bands were excised using a razor blade from the 
gel, and the product contained in the gel band was then extracted using the 
StrataPrep DNA Gel Extraction Kit (Agilent Technologies) following the 
manufacturer’s protocol.  
2.2.6. DNA Ligation 
 DNA Ligation was used to insert cDNA into each requisite plasmid. For 
insertion of PCR product into the TA TOPO vector (Life Technologies), the 
standard protocol provided by the manufacturer was followed. For insertion into 
the pHAGE-2 vector, 14µL of purified insert, 3µL purified vector, and 1µL T4 
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Ligase (NEB) were mixed together along with the requisite 2µL of 10x reaction 
buffer and incubated overnight in a water bath placed in the 4°C refrigerator. 
2.2.7. Bacterial Transformation 
 Bacterial transformation was used to produce stocks of new plasmids as 
well as to replenish stocks of already verified plasmids that had been used for 
other experiments. For transformation of the TA TOPO vector containing insert, 
1µL of ligation reaction was added to a vial of OneShot Mach1-T1R competent 
bacteria (Life Technologies), and the manufacturer’s protocol was followed. For 
all transformations or retransformations, 5µL of ligation reaction or 1µL of purified 
plasmid (respectively) was transformed into 50µL DH5α-chemically competent 
bacteria (Life Technologies). Briefly, the cells with plasmid were incubated on ice 
for 30 minutes, followed by a 30 second heat-shock at 42°C. The cells were 
transferred back to the ice for 2 minutes, after which 250µL of SOC media (Life 
Technologies) was added to the cell suspension and incubated with shaking at 
37°C for 1 hour. Finally, 100mL of this suspension was spread onto pre-warmed 
LB-Agar (MP Biomedials, Carlsbad CA) plates containing selection antibiotic 
(50µg/mL ampicillin for pHAGE2 vectors and lentiviral packaging vectors; 
34µg/mL chloramphenicol for shRNA vectors) and then incubated overnight at 
37°C to allow colony formation. 
2.2.8. Minipreps 
 The following protocol was used for preparations of previously 
nonvalidated (by sequencing) plasmids. Individual Colonies of transformed 
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bacteria were picked from the selection plate and added to 4mL of LB broth with 
respective antibiotic, which was incubated overnight at 37°C at 200 rpm in an 
environmental shaker. The vial was then centrifuged at 5000 rpm for 15 minutes 
at RT to separate cells from media. The plasmid DNA contained within the 
bacterial pellet was then isolated using the Qiaprep Spin Mini Kit (Qiagen) while 
following the standard manufacturer’s protocol. Plasmid DNA was eluted from the 
spin column in the final step using 50µL of RT water, and the DNA was assayed 
for concentration using the Take3 Microvolume plate as described above before 
being stored at -20°C until used. 
2.2.9. Midipreps 
 The following protocol was used for preparations of sequence-validated 
plasmids. Colonies of transformed bacteria were picked from selection plates and 
added to 100mL of LB broth with respective antibiotic, which was incubated at 
37°C. The flask containing the cell suspension was split between two 50mL 
centrifuge tubes and spun at 4500 rpm for 15 minutes at RT. Plasmid DNA was 
isolated using the Wizard Plus Midipreps DNA Purification System (Promega) 
and following standard manufacturer’s protocol. Plasmid DNA was eluted from 
the spin column with 300µL of 65°C water and the DNA was assayed for 
concentration using the Take3 Microvolume Plate before being stored at -20°C 
until used. 
2.2.10. Plasmid DNA Validation Sequencing 
 Insertion and sequence of the cDNA contained within the cloned plasmids 
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was validated using Sanger sequencing performed at the Tufts University Core 
Facility DNA Sequencing Lab (Boston, MA). 
2.3. Cell Culture 
2.3.1. Maintenance of Immortalized Cell Lines 
 HEK293FT cells were purchased from Life Technologies (Cat # R700-07), 
while Pheochromocytoma (PC) 12 cells were a generous gift from the Trinkaus-
Randall Lab at Boston University. Cells were cultured in T-75cm2 flasks in 
complete growth media containing Dulbecco’s modified Eagle’s media (DMEM) 
(Life Technologies) supplemented with 10% (HEK293FT) or 20% (PC12) fetal 
bovine serum (FBS) (Atlanta Biologicals, Flowery Branch GA) and 1% penicillin-
streptomycin (Life Technologies) at 37°C and 5% CO2. HEK293FT cells 
additionally were cultured with 500µg/mL Geneticin (Life Technologies) to 
maintain expression of the SV40 large T antigen stably expressed in these cells.  
 Cells were grown until they reached 80-90% confluency at which point 
they were split (approximately every 3 to 4 days). To split, cells were washed 
with Dulbecco’s phosphate buffered saline (DPBS) (Life Technologies) and then 
cell adhesion proteins were removed by incubation with 0.25% Trypsin-EDTA 
(Life Technologies) for 4 minutes at 37°C. Afterwards, 9mL of fresh growth media 
was added to cells and pipetted up and down to dislodge cells. Finally, 1mL of 
the cell suspension was transferred to a new 10cm T-75cm2 flask containing 
fresh growth media to propagate the cells further.  
 To freeze cells for storage, the same process was used for cell growth; 
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however, cells were grown to 100% confluence, trypsinized as described above, 
dislodged from the flask into a cell suspension, and then pipetted into a 15mL 
conical tube. The cell suspension was centrifuged for 2 minutes at 1200 rpm, 
upon which the supernatant media was removed and the cell pellet resuspended 
in freezing media composed of 40% complete growth media, 50% additional FBS, 
and 10% DMSO. Aliquots of 1mL were distributed to cryogenic tubes (Corning, 
Corning NY) and placed into isopropanol bath at -80°C overnight, after which 
they were transferred to cryogenic storage at -150°C. 
 To thaw and bring up cells from cryogenic storage, a cryotube containing 
the cells was transferred immediately to 37°C water bath; as the suspension 
completed thawed, the cells were transferred to a 15mL centrifuge tube within 
which 9mL of complete media was added. After spinning the tube at 1200 rpm for 
2 minutes, the supernatant media was removed, the cells were resuspended in 
complete media, and they were transferred to a new flask to allow for growth. 
2.3.2. Transfection of PC12 cells 
 To assess which shRNA lentiviral backbone plasmids had the strongest 
knockdown effect on GAK, transient transfection of each plasmid was performed 
in PC12 cells. Briefly, a confluent plate of PC12 cells was split, and 500,000 cells 
were plated onto a 6-well culture plate with 2mL of complete PC12 media. After 
24 hours, the cells were ready for transfection; a transfection solution was made 
by adding 1.2µg of shRNA plasmid DNA and 4.5µL of Attractene Transfection 
Reagent (Qiagen) to 100µL of pre-warmed OPTI-MEM+Glutamax-1 media (Life 
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Technologies). The mix was briefly vortexed and allowed to incubate at RT for 10 
minutes, after which it was added drop-wise to the plated PC12 cells. Prior to 
addition of the DNA/reagent complexes, the media on the cells was replaced with 
fresh PC12 media. After 48 hours, mRNA and protein from the cells were 
collected as described below to assess expression.  
2.3.3. Lentiviral Packaging 
 The following protocol was used to create non-replicative lentiviral 
particles for infection. A confluent plate of HEK293FT cells was dislodged of cells 
and cells were counted using a hemocytometer; twelve million cells were then 
plated onto 15cm culture plates with complete media and allowed to grow for 24 
hours. The number of plates used equaled the number of viral particles 
generated (four). After 24 hours of growth, cells were transiently co-transfected 
with plasmid DNA to allow for viral proteins to be generated. Briefly, 1.2µg each 
of tat, rev, and hgpm2 plasmid DNA, 2.4µg of vsv-g plasmid DNA, and 24µg of 
the lentiviral backbone plasmid DNA (either the pHAGE-2 plasmids or shRNA 
plasmids) were added to 2mL of pre-warmed OPTI-MEM+Glutamax-1 media. To 
this mix was added 112.5µL Attractene; the solution was briefly vortexed and 
incubated at room temperature for 10 minutes. This solution containing the 
DNA/reagent complexes was then added drop-wise to the plate of HEK293FT 
cells, and these were allowed to incubate at 37°C for 24 hours.  
 Twenty-four hours post-transfection, the media over the cells was 
replaced with 15mL fresh complete media, which was collected after 12 hours. 
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These collections were repeated twice more. After the last collection, the 45mL of 
conditioned media containing the viral particles was filtered through a 0.45µm 
filter, and ultra-centrifuged in an SW28 swing bucket rotor for 90 minutes at 
16500 rpm (48960xg). The supernatant was poured off, and the pellet containing 
the viral particles was resuspended in residual media (about 180µL), aliquoted 
(15µL each), and stored at -80°C until used. 
2.3.4. Lentiviral Titering 
 To assess the titer of lentiviral particles in the concentrated media, an 
ELISA assay was used to detect p24, a protein component of the viral particle’s 
capsid. The assay used was the Quicktiter Lentivirus Titer Kit (Cell Biolabs, San 
Diego CA), which detects only particle-associated p24, and not free p24 
generated by the HEK293FT cells. Titers of virus were determined based on a 
p24 standard curve, and used for infection of primary cultures. 
2.3.5. Isolation and Culture of Primary Rat Cortical Neurons 
 This procedure was used to generate primary cultures of rat cortical 
neurons derived from embryonic day 18 (E18) rat pups in accordance with an 
approved IACUC protocol. Female Sprague-Dawley rats pregnant at E18 were 
sacrificed using CO2 asphyxiation, followed by decapitation using a rat guillotine. 
The abdominal cavity was opened with tissue forceps and surgical scissors, the 
embryonic sac containing the pups was excised from the abdominal cavity, and it 
placed on a dissection dish, which was then placed on ice. 
 The whole brain from each individual pup was then extracted using fine 
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and curved forceps. First, the skin and skull was pulled away from the posterior 
portion of the head, followed by the scooping of the brain from the skull cavity 
using the curved forceps. The brains were then placed into cold sterile-filtered 
calcium- and magnesium-free Hank’s Balanced Salt Solution (CMF-HBSS) (1x 
HBSS, 4.2mM Sodium Bicarbonate, 1mM Sodium Pyruvate, 20mM HEPES, 
3mg/mL Bovine Serum Albumin (BSA), pH 7.3) and were not exposed to air post-
extraction. All dissections proceeded using a dissection microscope upon which 
was placed a 35mm petri dish containing cold CMF-HBSS that was continually 
replenished. 
 In order to dissect cortex from the whole brain, the cerebellum was first 
removed using the fine and curved forceps, followed by a mid-sagittal cut to 
separate the two hemispheres of the cortex and removal of the midbrain and 
pons. The meninges surrounding the cortex was carefully removed to prevent 
contamination of the culture with fibroblasts. Finally, the hippocampus, which 
appears as a dark ribbon near the ventricle, was carefully excised as well, 
leaving the cortex. 
 The dissected cortices were placed in a 15mL centrifuge tube in CMF-
HBSS, and centrifuged for 1 minute at 1000 rpm. The supernatant above the 
cortical pellet was removed, the pellet washed with 10mL cold CMF-HBSS, and 
then centrifuged again. After this centrifugation, the pellet was incubated with 
2mL pre-warmed 0.05% Trypsin-EDTA (Life Technologies) for 9 minutes at 37°C, 
with swirling every 3 minutes. The trypsin was neutralized with neuronal plating 
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media composed of Neurobasal-A media (Life Technologies) containing 10% 
FBS and 1% penicillin-streptomycin. The now trypsinized cell mass was 
centrifuged again to remove the supernatant, and then 2mL of neuronal feeding 
media composed of Neurobasal A media containing 1x B-27 Serum-Free 
supplement (Life Technologies) and 1% penicillin-streptomycin was added. The 
cell mass was dissociated by triturating the clump through first a 5mL serological 
pipette, then a 2mL serological pipette, and finally a 1mL pipette, taking care to 
not form bubbles and using the tube wall to break up clumps. 
 After trituration, the cell suspension was passed through a 70µm cell 
strainer (BD Biosciences, Franklin Lakes NJ) and diluted in neuronal feeding 
media. Cells were counted using a hemocytometer and two million cells were 
plated per well of 6-well poly-D-lysine pre-coated culture plates in 2mL of feeding 
media. The cells were maintained and allowed to differentiate in a 37°C incubator 
with 5% CO2, and their media was half changed (removing half the conditioned 
media and replacing with fresh feeding media) every 3-4 days. 
2.3.6. Co-infection of Primary Neuronal Cultures 
 After seven days in vitro (DIV), the primary cortical neurons were co-
infected with the lentiviral particles produced as described above. Four different 
experimental conditions were tested, representing all possible combinations of 
over-expressing pHAGE plasmids with the shRNA plasmids (one plasmid 
targeting GAK, one non-targeting control). Briefly, 30 million particles per each 
lentiviral backbone construct were diluted into 1mL fresh pre-warmed feeding 
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media. Because a co-infection was performed, the total number of particles per 
condition was 60 million. One half of the conditioned media was removed from 
the primary cultures and replaced with the media containing the viral particles. 
The conditioned media removed was stored at 37°C overnight. The viral 
transduction was allowed to proceed for 24 hours at 37°C.  
 After 24 hours post initial infection, the viral particles were removed from 
the neurons and the media replaced with the stored conditioned media 
supplemented with fresh feeding media to a total volume of 2mL. At 48 hours 
post-infection, 0.125µg/mL Puromycin (Life Technologies) selection antibiotic 
was added to the cells to select for only those cells transduced with the shRNA 
lentiviral backbones. At 96 hours post-infection, the cells were harvested for 
mRNA and protein as described below. 
2.3.7. Collection and Preparation of Total RNA 
 This protocol describes the procedure used to collect total RNA from 
cultured cells. Plates of cells ready to be harvested were first placed on ice; 
these cells were gently washed twice with cold Phosphate Buffered Saline (PBS) 
and lysed with 350µL of RLT lysis buffer provided in the RNeasy Mini Kit 
(Qiagen). The lysate was homogenized using an 18-gauge needle and syringe 
system as described in the protocol provided by the manufacturer, and the 
remainder of the manufacturer’s protocol was followed. Total RNA was eluted 
using 50µL RNase-free water, and the quantity of RNA was assessed using the 
Take3 Microvolume plate and Biotek Microplate reader. This RNA was stored at  
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-80°C until used. 
2.3.8. Collection and Preparation of Total Protein 
 The following protocol was used to collect total protein from cultured cells. 
Briefly, plates of cells ready to be harvested were first placed on ice; these cells 
were gently washed twice with cold PBS and lysed with 250µL of Radio-
immunoprecipitation assay (RIPA) buffer (50mM Tris-Hydrochloride pH 7.4, 
150mM Sodium Chloride, 1% Triton-X100, 1% Sodium Deoxycholate, and 0.1% 
Sodium Dodecyl Sulfate in water) supplemented with cOmplete Mini Protease 
Inhibitor Cocktail with EDTA (Roche Applied Science, Indianapolis, IN) and 
PhosSTOP Phosphatase Inhibitor Cocktail (Roche Applied Science). The lysate 
was incubated on ice for 30 minutes, vortexing every 10 minutes, and then 
centrifuged at 14000 rpm for 15 minutes at 4°C. The resulting supernatant 
containing the protein was transferred to a new 1.5mL tube and stored at   
-80°C until used. 
2.4. Quantitative Real-Time PCR 
 To quantify expression of specific mRNA’s, quantitative real-time PCR 
(qRT-PCR) was used. First, one microgram of total RNA was reverse-transcribed 
to 1µg cDNA using iScript Reverse Transcription Supermix (Bio-Rad, Hercules 
CA), and the manufacturer’s standard protocol was followed. The reaction 
required a priming step at 25°C for 5 minutes, followed by reverse transcription at 
42°C for 30 minutes, and finally inactivation at 85°C for 5 minutes. The resulting 
cDNA was diluted to 10ng/µL and stored at -20°C until used. 
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 To perform the PCR step, Taqman Gene Expression Assays (Life 
Technologies) were employed, and samples were assayed on the Applied 
Biosystems 7900HT Fast Real-Time PCR System (Life Technologies). A list of all 
Taqman assays used can be found in Table 5. Briefly, the assay and sample mix 
consisted of 1µL of the Taqman 20x assay, 30ng of each sample’s cDNA, 10µL  
Table 5. Taqman Assays Used for PCR. 
 
of the Taqman Gene Expression Mastermix (Life Technologies), and water to a 
final volume of 20µL. Each reaction was carried out in a 384-well reaction plate, 
and the PCR conditions were as follows: a holding step at 50°C for 5 minutes, 
followed by an initial denaturation step at 95°C for 10 minutes, and then 40 
cycles of amplification comprised of 15 seconds of denaturation at 95°C and 1 
minute of annealing/extension at 60°C. 
 To perform the quantitative analysis, the number of cycles to threshold 
(CT) fluorescence was determined for each sample and it’s requisite assays. The 
ΔΔCT method for quantitative analysis was employed, which requires first taking 
the difference in CT values (ΔCT) between a target assay and the endogenous 
control assay for a given sample, and then taking the difference of the ΔCT’s 
between a given experimental sample and the average ΔCT’s of the control 
Taqman Assay Number Species Gene RefSeq Exon Junction
Fluorescent 
Dye
Rn00667456_g1 Rat GAK 27-28 FAM
Rn01425140_m1 Rat SNCA 2-3 FAM
Rn00667869_m1 Rat ACTB 4-5 FAM
Hs01103383_m1 Human SNCA 2-3 FAM
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samples (the ΔΔCT). Fold change (FC) was determined by the following 
equation: FC = 2(-ΔΔCT), and differences in fold change between conditions were 
assessed using an unpaired two-tailed T-test (differences were deemed 
significant at p-value less than 0.05). 
2.5. Protein Analysis by Western Blot 
2.5.1. Bicinchonic Acid Assay 
 The Bicinchonic Acid (BCA) Protein Assay (Pierce Biotechnology, 
Rockford IL) was used to quantify total protein collected from cells, and the 
manufacturer’s protocol was followed. Each of the samples was aliquoted at 
10µL in duplicate onto a flat-bottomed 96-well assay plate, and absorbance 
readings were obtained at 562nm using the Synergy Plate reader, which were 
then used to quantify each sample according to a standard curve created using a 
BSA standard. 
2.5.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
 To assay for protein expression, the proteins contained in the lysates were 
first separated by molecular weight using Sodium Dodecyl Sulfate (SDS) 
Polyacrylamide Gel Electrophoresis (PAGE). Tris-Glycine SDS gels containing 
12% Polyacrylamide were prepared using the Bio-Rad Mini-Protean Tetra 
System according to the recipe calculated by the SDS-PAGE website 
(http://www.changbioscience.com/calculator/sdspc.htm). Each gel was prepared 
using HPLC Grade Water (Fisher Scientific, Waltham MA), 30% UltraPure 
Protogel (National Diagnostics, Atlanta GA), 10% SDS (Fisher Scientific), 10% 
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Ammonium Persulfate (Sigma-Aldrich, St. Louis MO), TEMED (Sigma-Aldrich) 
and Tris-Hydrochloride (Fisher Scientific). 
 Proteins were denatured using 5x Laemmli buffer (250mM Tris-HCl at pH 
6.8, 10% SDS, 30% Glycerol, 5% beta-mercaptoethanol, 0.02% bromophenol 
blue) and heated to boiling for 5 minutes. Approximately 25µg of protein sample 
was loaded into each well of a Tris-Glycine gel along with 8µL of Bio-Rad 
Precision Plus Protein WesternC Standard (which was used as a protein ladder 
to estimate molecular weights after visualizing the protein bands). Proteins were 
separated in 1x Tris-Glycine SDS-PAGE Running buffer (25mM Tris Base, 
192mM Glycine, 0.1% SDS) for 70 minutes at 150V. 
2.5.3. Protein Transfer and Western Blotting 
 The proteins now separated in the gel by SDS-PAGE were transferred to 
nitrocellulose membrane for further analysis using Western Blotting. Briefly, Tris-
Glycine gels were sandwiched with 0.4µm Immobilon Hybridization nitrocellulose 
membranes (EMD-Millipore, Billerica MA) and proteins transferred at 100V for 
100 minutes in Tris-Glycine Transfer Buffer (25mM Tris Base, 192mM Glycine, 
20% Methanol). After transfer, the membranes were washed with Tris-Buffered 
Saline (10mM Tris-Hydrochloride pH 8, 150mM Sodium Chloride) (TBS) with 
0.05% (v/v) Tween-20 (TBS/T) for 10 minutes at RT. The membranes were then 
incubated with 5% non-fat dry milk in TBS/T for two 30-minute periods at RT, 
followed by two washes with TBS/T and addition of the primary antibody 
(described below) for overnight incubation with shaking at 4°C.  
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 On the following day, the primary antibody was removed and the 
membranes were washed twice with TBS/T followed by a 1-hour incubation at 
RT with the secondary HRP-conjugated antibody (described below). After 
incubation, the membranes were washed four times with TBS/T, and then 
incubated for 5 minutes with either the Supersignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Waltham MA) or the Immobilon Western 
Chemiluminescent HRP Substrate (EMD-Millipore), depending on the protein 
band signal intensity desired. Membranes were developed using the ChemiDoc 
XRS+ Molecular Imager with Image Lab Software (Bio-Rad). Densitometry was 
performed on desired bands using ImageJ software91 and relative expression 
was assessed by measuring the ratio of the area of the target protein band to the 
control protein band. 
 All primary antibodies were prepared in TBS/T with 3% BSA and 0.03% 
sodium azide. A-synuclein protein was detected using the mouse monoclonal α-
synuclein antibody clone 42 (BD Biosciences) at a dilution of 1:1000. GAK 
protein was detected using the mouse monoclonal GAK antibody clone 1C2 
(1:1000) (Abcam, Cambridge UK). In order to normalize expression of target 
proteins across lanes, the endogenous control protein β-actin was used and 
detected with mouse monoclonal β-actin antibody clone AC-74 (1:5000) (Sigma-
Aldrich). Goat anti-mouse secondary antibodies conjugated to horseradish 
peroxidase (HRP) were prepared in TBS/T with 5% non-fat dry milk and 0.03% 
sodium azide and obtained from KPL (Gaithersburg, MD). 
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2.6. Gene Expression Microarray 
2.6.1. RNA Preparation and Hybridization 
 Quantified RNA derived from rat cortical neurons and qualified for 
knockdown of GAK and over-expression of α-synuclein by qRT-PCR were 
prepared for analysis on the Affymetrix (Santa Clara, CA) GeneChip Rat Gene 
2.0 ST array. Briefly RNA integrity was characterized using the Agilent 2100 
Bioanalyzer as described above. After the RNA was determined to be of 
sufficient quality, the samples were processed by the BU Microarray Core Facility 
(Boston, MA), which included poly-adenylated mRNA selection, cDNA synthesis, 
and cDNA library coupling as described by the manufacturer. The cDNA was 
then hybridized to 610,400 probes covalently bonded to the gene chip, whereby 
fluorescent signals were produced that were detected using the Affymetrix 
GeneChip Instrument System. 
2.6.2. Microarray Data Analysis 
 The raw intensity data for each sample derived from the GeneChip was 
compiled together and each probeset annotated to a single Ensembl ID based on 
a custom rat Chip Description File (CDF) from the Microarray Lab of the 
Molecular and Behavioral Neuroscience Institute at the University of Michigan 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF_d
ownload.asp) using the ReadAffy wrapper function implemented in the R 
package affy92. The raw data was assessed for quality using two different 
metrics: Normalized Unscaled Standard Error (NUSE), which measures the 
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relative chip quality derived from the standard error estimates of each gene in 
each array normalized to the median standard error for that gene in all arrays, 
and Relative Log Expression (RLE), which gauges the variability of expression by 
comparing the probeset expression within a particular array against the median 
expression of that probeset across all arrays studied. Raw intensity data was 
next normalized using the robust multi-array average (RMA)93 function 
implemented in affy.  
 After normalization, genome-wide differential expression among 
conditions was assessed using two different strategies: first, pair-wise contrasts 
between all conditions using a linear modeling approach and empirical Bayes 
statistics94 were performed using functions implemented in the R package 
limma95; second, GLMs assuming log-normally distributed data (implemented in 
the R package MASS) and using SNCA over-expression and GAK expression as 
independent variables were used to assess their relationships to gene 
expression. All results were adjusted for multiple comparisons using FDR, 
whereby p-values were deemed genome-wide significant if less than 0.05. Genes 
found to be genome-wide significantly associated with GAK expression or 
nominally associated with SNCA expression were analyzed further using the 
pathway analysis tools DAVID and IPA. 
 Association analyses between GAK expression and candidate gene 
expression were performed using gene lists curated from either STRING (for 
annotated GAK-interacting genes) or Swissregulon Database96 (for predicted 
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transcription factors regulating SNCA expression). Analyses for association to 
GAK expression were performed using GLMs assuming a log normal distribution, 
with SNCA over-expression and GAK expression as independent variables, and 
results were adjusted for the number of comparisons in each case. 
 Finally, the genes with greater than 50% of their exons genome-wide 
significantly associated to GAK expression in the RNA-Seq study were compared 
to genome-wide significant genes associated with GAK in the microarray study. 
Common genes between the two studies were assessed to determine the 
direction of effect, and those with common effect directions were analyzed for 
shared pathways using DAVID and IPA as described above. 
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CHAPTER THREE – RESULTS 
1. Decreased GAK Expression is Associated with 4p16.3 PD Risk SNPs and 
 Increased Expression of SNCA 
1.1. Human Brain Sample Characteristics 
 Human cortical samples studied using RNA-sequencing were assessed 
for differences between cases and controls in PMI, age at death, and rs1564282 
risk SNP genotype using logistic regression analysis. The age at death was 
found to be significantly different between cases and controls, while the PMI and 
risk SNP minor allele frequencies (MAF) were not found to be significantly 
different (Table 6). As PMI was previously reported to influence expression in 
post-mortem brain tissue97, all subsequent association analyses were adjusted 
for PMI and age at death. 
Table 6. Human Brain Sample Covariate Summary Statistics. ** = 
significantly different between cases and controls ; MAF = Minor Allele 
Frequency. 
 
 
 
1.2. Gencode Annotated Exon Expression in the 3’ region of GAK is Associated 
with Case Status and Risk SNP rs1564282 
 The expression of Gencode annotated exons in GAK (normalized using 
DEXSeq) was first evaluated for association to case status in all samples utilizing 
a GLM analysis assuming a negative binomial distribution. After adjusting for 
Covariates Controls PD p-value
Mean Age at Death (years) 68.3 77.6 0.009**
Mean PMI (hours) 15.0 11.1 0.092
rs1564282, MAF 0.14 0.19 0.464
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multiple comparisons, twenty-six out of seventy-one exons in GAK were found to 
have increased expression in PD as compared to control (Figure 4); additionally, 
none of the exons in GAK showed significantly decreased expression in PD. 
Interestingly, the majority of the exons with increased expression lie in the 3’ 
region of GAK and many are contiguous with one another, while the exons in the 
5’ end of GAK are increased in expression but lowly expressed overall. 
 In order to assess the effect of the risk SNP rs1564282 on the expression 
profile of GAK in cases and controls, the exons were next evaluated for 
association to case status after stratifying by rs1564282 genotype and for 
association to rs1564282 after stratifying by case status. In control samples only, 
the risk SNP is associated with the increased expression of just two GAK exons 
in the 3’ region (Table 7). None of the exons showed association to the risk SNP 
in just the PD samples after adjusting for multiple comparisons. In homozygote 
carriers of the WT allele of the risk SNP, most of 3’ exons in GAK showed 
significantly increased expression in PD as compared to controls, a result similar 
to what was observed in the combined sample set (Table 7). Interestingly, in risk 
allele carriers, only one of the exons reached significance for increased 
expression, although the other exons all trended in the same direction. 
 In order to simultaneously assess association to case status and the GAK 
locus risk SNP, a multivariable GLM analysis was performed, adjusting for age at 
death and PMI. Two exons, 25 and 26, showed significant association to both 
case status and to the risk SNP after adjusting for multiple comparisons.  
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Figure 4. GAK Gencode Exons in the 3’ Region are Increased in PD. The 
mean normalized expression for PD cases and controls was plotted for each of 
the 71 GAK exons (x-axis). Exon 1 corresponds to the 3’ end of the gene, while 
Exon 71 corresponds to the 5’ end. Brackets indicate groups of exons 
significantly associated to case status ( * = p-value < 0.05). 
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Table 7. Association of GAK Gencode Exons 1-40 Expression to risk SNP 
rs1564282 and Case Status, Stratified Analyses. (β-est = beta estimate; cells 
highlighted in yellow are significantly associated with the risk SNP, while those 
highlighted in blue are associated with case status at FDR adjusted p-value < 
0.05). 
 
 
 
 
 
 
Control      
β-est
Control      
p-value
PD             
β-est
PD            
p-value
WT allele 
β-est
WT allele 
p-value
Risk Carrier          
β-est
Risk Carrier 
p-value
1 0.46 0.56 -0.76 0.75 0.43 0.56 -0.82 0.56
2 0.13 0.89 -0.29 0.86 0.38 0.56 0.38 0.73
3 -0.17 0.56 -0.11 0.86 0.47 < 0.01 0.87 < 0.01
4 -0.12 0.56 -0.22 0.31 0.41 < 0.01 0.43 0.09
5 -0.08 0.64 -0.17 0.31 0.31 < 0.01 0.32 0.10
6 -0.17 0.62 -0.18 0.79 0.38 0.12 0.73 0.07
7 -0.21 0.56 -0.09 0.86 0.25 0.41 0.56 0.09
8 -0.08 0.61 -0.16 0.31 0.27 < 0.01 0.27 0.11
9 -0.09 0.56 -0.15 0.31 0.27 < 0.01 0.27 0.09
10 -0.01 0.98 0.11 0.84 -0.13 0.49 0.13 0.73
11 0.05 0.87 -0.03 0.91 -0.18 0.37 -0.21 0.59
12 -0.05 0.72 -0.16 0.31 0.30 < 0.01 0.23 0.10
13 0.00 0.98 -0.11 0.31 0.28 < 0.01 0.20 0.11
14 0.00 0.98 -0.08 0.59 0.27 < 0.01 0.21 0.11
15 0.03 0.93 -0.13 0.74 0.36 < 0.01 0.21 0.54
16 0.21 0.44 0.17 0.74 -0.05 0.85 -0.45 0.10
17 -0.02 0.89 -0.05 0.79 0.24 < 0.01 0.25 0.09
18 0.03 0.81 -0.10 0.40 0.28 < 0.01 0.17 0.25
19 0.02 0.87 -0.10 0.31 0.23 < 0.01 0.18 0.17
20 0.04 0.81 -0.06 0.79 0.22 0.01 0.24 0.10
21 0.05 0.64 -0.13 0.31 0.21 < 0.01 0.13 0.37
22 0.07 0.56 -0.08 0.69 0.19 < 0.01 0.12 0.40
23 0.02 0.87 -0.05 0.83 0.18 0.01 0.14 0.23
24 0.10 0.35 0.01 0.99 0.19 < 0.01 0.09 0.47
25 -0.25 0.28 -0.60 0.08 0.61 < 0.01 0.46 0.22
26 0.15 0.04 0.02 0.86 0.17 < 0.01 0.07 0.56
27 -0.95 0.15 -0.63 0.59 -0.15 0.80 -0.13 0.87
28 0.12 0.22 -0.02 0.86 0.17 < 0.01 0.06 0.69
29 0.11 0.26 0.03 0.86 0.17 < 0.01 0.09 0.56
30 0.10 0.48 0.06 0.81 0.17 0.05 0.17 0.25
31 0.10 0.54 0.08 0.75 0.11 0.34 0.05 0.79
32 0.09 0.56 0.10 0.74 0.06 0.71 0.02 0.88
33 0.08 0.56 0.04 0.86 0.03 0.85 -0.04 0.82
34 0.09 0.56 0.07 0.84 -0.02 0.85 -0.10 0.64
35 0.13 0.41 0.10 0.80 0.00 0.97 -0.06 0.79
36 0.77 0.15 -0.01 1.00 0.69 0.05 0.30 0.62
37 0.63 0.04 0.20 0.79 0.42 0.04 -0.15 0.79
38 0.09 0.56 0.13 0.75 -0.05 0.80 -0.11 0.64
39 0.15 0.35 0.13 0.62 -0.03 0.85 -0.15 0.40
40 0.21 0.22 0.15 0.59 0.09 0.60 -0.09 0.65
Association to risk SNP Association to Case StatusGAK 
Exon
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Intriguingly, exon 25 expression was increased in PD relative to controls (β-est = 
0.57, p-value = 5.9x10-5), but was decreased in risk SNP carriers as compared to 
non-carriers (β-est = -0.43, p-value = 0.01), with the greatest change occurring 
between PD major allele homozygotes and PD minor allele homozygotes (Figure 
5).  
 As the exons in the 3’ region of GAK are constituents of larger transcripts, 
the expression of exon 25 in GAK is not independent of the expression of these 
other 3’ exons. Therefore, a Pearson correlation was performed to assess the 
relationship between exon 25 expression in GAK and the expression of all the 
other GAK exons (Table 8). Unsurprisingly, almost all of the significantly 
associated exons (FDR adjusted p-value less than 0.05) showed a positive 
correlation with exon 25, indicating co-expression of these 3’ exons with one 
another, which is presumably a consequence of these exons being spliced to 
form transcripts in both normal and diseased brain tissue. 
1.3. Assessment of Risk SNP Association to other Genes in the 4p13.6 Locus 
 Because the risk SNP tested is in high linkage disequilibrium with other 
SNPs throughout the 4p16.3 locus, it was unclear whether it (and by proxy the 
other SNPs) might exert an effect on other genes nearby to its position. In order 
to clarify the role rs1564282 might play in influencing expression of these genes, 
analyses were performed on the exons in GAK, TMEM175, DGKQ, SLC26A1, 
and IDUA for association to both the risk SNP and case status. After adjusting for 
multiple comparisons, only exon 25 in GAK showed significant association to the  
 55 
 
 
Figure 5. GAK Gencode Exon 25 Expression is Decreased in Minor Allele 
Carriers of Risk SNP rs1564282. The mean normalized expression of exon 25 
was plotted for the each of the stratified groups. The samples were stratified by 
case status (Control and PD) and by genotype in an additive fashion (CC = Major 
Allele Homozygote, CT = Heterozygote, TT = Risk Allele Homozygote).  
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Table 8. GAK Gencode Exons Significantly Correlate with GAK Gencode 
Exon 25 by Pearson Correlation. (r-value = Pearson correlation coefficient).  
 
 
 
 
 
Exons r-value p-value
3 0.31 0.02
4 0.37 < 0.01
5 0.45 < 0.01
6 0.46 < 0.01
7 0.43 < 0.01
8 0.44 < 0.01
9 0.38 < 0.01
12 0.39 < 0.01
13 0.34 < 0.01
14 0.39 < 0.01
15 0.45 < 0.01
17 0.38 < 0.01
18 0.47 < 0.01
19 0.51 < 0.01
20 0.48 < 0.01
21 0.63 < 0.01
22 0.55 < 0.01
23 0.52 < 0.01
24 0.40 < 0.01
26 0.27 0.04
27 0.29 0.02
29 0.35 < 0.01
30 0.48 < 0.01
36 0.59 < 0.01
37 0.40 < 0.01
42 0.30 0.02
43 0.30 0.02
44 0.39 < 0.01
53 -0.29 0.02
57 0.43 < 0.01
58 0.35 < 0.01
59 0.51 < 0.01
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risk SNP (p-value = 0.03); surprisingly, out of 207 exons analyzed, 23 of the 
exons in the 3’ region of GAK previously mentioned and a single exon in 
SLC26A1 showed significant association to case status, indicating differential 
exon expression in this chromosomal region between cases and controls occurs 
primarily in the GAK gene. 
1.4 Expression of Gencode Exon 25 in GAK is Associated with SNCA Gencode 
Exon Expression and with Known GAK- and SNCA-interacting Genes 
 In order to understand how the expression of GAK exon 25, and by 
extension the 3’ exons in this gene, may be related to the expression of other 
genes, association analyses were performed for exons in genes with known 
functional association to GAK derived from the protein association database 
STRING (Table 3). After removal of exons with zero counts, 988 exons from 23 
genes were analyzed for association to expression of GAK exon 25, adjusting for 
case status, age at death, and PMI. Genes with significantly associated exons 
(FDR adjusted p-value less than 0.05) with mean normalized counts greater than 
ten are listed in Table 9. A number of these genes have very few exons 
associated with GAK exon 25 expression, while others, such as CDK5 and 
SNAP91 (AP180 protein), have a large percentage of exons that are related to 
GAK exon 25 expression. Additionally, some of the exons in genes including 
DNM2, HIP1, and HIP1R show a direct relationship with GAK expression, while 
others such as SNAP91, CDK5, and AP2M1 show an inverse relationship to 
GAK expression.  
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Table 9. GAK-interacting Candidate Genes containing Exons Significantly 
Associated with Expression of GAK Gencode Exon 25 in Control and PD 
Brains. Direction of Association indicates the sign of the β-estimates for the 
association of GAK exon 25 with the exons of that specific gene. Exons were 
deemed significant if their FDR adjusted p-value was less than 0.05. 
  
 
 
 
 
 
 
 
 
 
 
Ensemble ID Gene Name
Percentage Exons 
Associated with 
GAK 25
Direction of 
Association
ENSG00000164885 CDK5 72.7% -
ENSG00000065609 SNAP91 54.9% -
ENSG00000127946 HIP1 53.7% +
ENSG00000079805 DNM2 48.6% +
ENSG00000161203 AP2M1 43.6% -
ENSG00000130787 HIP1R 40.0% +
ENSG00000145335 SNCA 34.6% -
ENSG00000005339 CREBBP 24.1% +
ENSG00000141367 CLTC 22.6% -
ENSG00000072958 AP1M1 17.4% -
ENSG00000105245 NUMBL 16.7% -
ENSG00000113328 CCNG1 16.7% +
ENSG00000109971 HSPA8 10.8% +
ENSG00000175166 PSMD2 8.7% -
ENSG00000138768 USO1 4.7% -
ENSG00000133961 NUMB 3.1% -
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 Interestingly, more than a third of the exons in SNCA show an inverse 
relationship with expression of exon 25 in GAK. To further investigate how GAK 
expression may impact SNCA expression in human prefrontal cortex, association 
analyses of GAK exon 25 to the exons of 40 genes with known functional 
association to SNCA (as designated by STRING) (Table 4) were performed, 
adjusting for case status, age at death, and PMI. Twelve genes contained exons 
significantly associated with GAK exon 25 (Table 10), including TOR1A 
(inversely related) and UBC (directly related). Three well-known PD genes 
contained exons within each gene with opposite direction of association with 
GAK exon 25 expression (UCHL1, PARK2, LRRK2) suggesting some transcripts 
of these genes are directly correlated with GAK exon 25 expression and others 
are inversely correlated with its expression. Nonetheless, the majority of the 
exons in SNCA interacting genes showed little to no association with GAK exon 
25, suggesting these SNCA-interacting genes may not be strongly affected by 
differential GAK expression. 
1.5. Knockdown of GAK in Primary Rat Cortical Neurons Increases Expression of 
Endogenous SNCA 
 While altering GAK expression has been observed to affect protein levels 
of α-synuclein and cellular viability in vitro78, it is unclear whether  
GAK or SNCA exert any transcriptomic control over each other. In order to better 
clarify the underlying functional relationship between these two genes and to 
model the effect of the risk SNP in reducing GAK expression in brain, human  
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Table 10. SNCA-interacting Candidate Genes with Exons Significantly 
Associated to Expression of GAK Gencode Exon 25 in Control and PD 
Brains. Direction of Association indicates the sign of the β-estimates for the 
association of GAK exon 25 with the exons of that specific gene (bi-directional 
indicates inconclusive directionality). Exons were deemed significant if their FDR 
adjusted p-value was less than 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Ensemble ID Gene Name
Percentage Exons 
Associated with 
GAK 25
Direction of 
Association
ENSG00000136827 TOR1A 58.3% -
ENSG00000154277 UCHL1 51.4% bi-directional
ENSG00000150991 UBC 47.1% +
ENSG00000185651 UBE2L3 20.0% -
ENSG00000116288 PARK7 17.9% +
ENSG00000112640 PPP2R5D 14.3% -
ENSG00000185345 PARK2 11.8% bi-directional
ENSG00000198873 GRK5 9.5% +
ENSG00000148180 GSN 7.8% +
ENSG00000188906 LRRK2 4.5% bi-directional
ENSG00000129219 PLD2 3.3% +
ENSG00000010810 FYN 1.2% +
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SNCA cDNA was over-expressed and rat GAK expression was knocked down 
via lentiviral transduction in cultured rat primary cortical neurons; their mRNA 
expression was then assessed by qRT-PCR.  
 GAK knockdown by shRNA resulted in an approximate 50% reduction in 
GAK expression, regardless of whether exogenous SNCA was co-expressed 
(Figure 6A). Exogenous SNCA was expressed at 5-fold greater levels than 
endogenous SNCA in cells expressing scrambled shRNA; however, when GAK 
was knocked down, this increase in expression was reduced to 3-fold (Figure 
6B). Interestingly, in neurons where GAK was knocked down, endogenous levels 
of SNCA mRNA were significantly increased when only ZsGreen was over-
expressed; when human WT SNCA was over-expressed, endogenous levels of 
SNCA were not significantly increased (Figure 6C). As GAK knockdown appears 
to increase endogenous SNCA mRNA, α-synuclein protein levels were also 
assessed by Western Blot for differences upon GAK knockdown in just ZsGreen 
over-expressing samples; levels of α-synuclein protein were slightly increased 
under these conditions (Figure 6D). 
1.6. Knockdown of GAK in Primary Rat Cortical Neurons Alters Expression of 
Transcription Factors Targeting SNCA 
 As GAK knockdown results in an increase in endogenous SNCA RNA 
levels, transcription factors targeting SNCA could also be affected by differential 
GAK levels. As annotated by the Swissregulon Database, there are many 
regulatory motifs, both in the promoter and throughout SNCA, that serve as  
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Figure 6. Decreased GAK mRNA Expression Results in Increased 
Endogenous SNCA mRNA and Protein Expression in Primary Cortical 
Neurons. Primary Cortical Neurons were transduced with lentivirus over-
expressing either ZsGreen as Control (ZsGreen) or WT human SNCA (WTsyn) 
and scrambled negative control shRNA (Control) or shRNA targeting RefSeq 
exon 5 of rat GAK (GAK). (A) Relative mRNA expression of GAK was measured 
using a Taqman assay probing the 3’ exons of GAK, normalized to ACTB as a 
control. (B) The ratio of expression of exogenous human SNCA to endogenous 
SNCA was measured using Taqman assays. (C) Relative mRNA expression of 
endogenous SNCA was measured normalized to ACTB as a control. (D) A-
synuclein expression was normalized to β-actin expression within condition, and 
the ratio of relative expression for each of the conditions was normalized to the 
control condition (ZsGreen-Control shRNA). n = 3 for conditions A-C, n=1 for 
condition D; * = p-value < 0.05, N.S. = not significant. 
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Table 11. Annotated Transcription Factor Binding Sites Nearby SNCA on 
Chromosome 4. All possible binding site positions within the SNCA region are 
listed for each group of genes with common motifs. Posterior Probability Score is 
the likelihood a binding site will occur at any given position. 
 
Gene(s) Chromosomal Location(s) 
Posterior 
Probability 
Score 
AHR, ARNT, ARNT2 90759357-90759362 0.21 
AIRE 90759657-90759681 0.67 
BPTF 90759557-90759570 0.86 
BPTF 90759559-90759572 0.67 
CDX1, CDX2, CDX4 90759559-90759576 0.24 
CREB1 90758026-90758037 0.07 
EBF1 90758740-90758761 0.92 
EGR1, EGR2, EGR3 90758358-90758369 1.00 
ELF1, ELF2, ELF4 90759520-90759526 0.81 
EOMES 90759435-90759443 0.32 
ESR1 90758554-90758571 0.20 
FOXC1, FOXC2 90759149-90759156 0.13 
FOXI1, FOXJ2 90759084-90759095 0.54 
FOXD3 90757950-90757961 0.18 
FOXD3 90759694-90759705 0.58 
FOXD3 90759084-90759095 0.68 
FOXD3 90759657-90759668 0.65 
FOXD3 90757949-90757960 0.28 
FOXN1 90759184-90759194 0.00 
FOXQ1 90759085-90759095 0.25 
GATA1, GATA2, GATA3 90759017-90759022 0.52 
GFI1 90758368-90758377 0.64 
GFI1B 90759185-90759196 0.08 
GLI1, GLI2, GLI3 90758723-90758734 0.98 
GTF2I 90759461-90759469 0.96 
HMGB2, HMGB3, SSRP1, UBTF, HBP1 90759371-90759376 0.46 
HMGA1, HMGA2 90757947-90757961 0.03 
HMGA1, HMGA2 90757950-90757964 0.02 
HMGA1, HMGA2 90759640-90759654 0.95 
HMGA1, HMGA2 90757952-90757966 0.06 
HMX1 90759260-90759269 0.13 
HMX1 90758242-90758251 0.54 
IKZF2 90757729-90757739 0.11 
KLF4 90758126-90758135 0.94 
KLF4 90759458-90759467 0.93 
MAFB 90759039-90759046 0.23 
MAZ 90758390-90758397 1.00 
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Gene(s) Chromosomal Location(s) 
Posterior 
Probability 
Score 
MYB 90759098-90759105 0.09 
MYBL2 90759893-90759901 0.14 
MZF1 90758313-90758325 0.95 
MZF1 90758671-90758683 0.79 
MZF1 90758616-90758628 0.96 
MZF1 90758677-90758689 0.86 
MZF1 90759397-90759409 0.60 
NANOG 90757886-90757892 0.01 
NFIX 90759872-90759900 0.00 
NKX2-2, NKX2-8 90757884-90757893 0.05 
NKX3-1 90757976-90757987 0.00 
NKX6-1, NKX6-2 90759648-90759660 0.13 
PAX5 90758391-90758410 0.86 
POU5F1 90759378-90759384 0.86 
RUNX1, RUNX2, RUNX3 90759678-90759686 0.28 
SNAI1, SNAI2, SNAI3 90758110-90758115 0.63 
SOX8, SOX9, SOX10 90759809-90759817 0.20 
SOX5 90759574-90759580 0.54 
SP1 90758622-90758635 0.94 
SP1 90757926-90757939 0.87 
SP1 90758353-90758366 0.93 
SP1 90759456-90759469 0.95 
SP1 90758386-90758399 0.98 
SPI1 90759399-90759409 0.90 
SRY 90759574-90759582 0.65 
TFAP2B 90758401-90758416 0.98 
TFDP1 90758641-90758646 0.79 
TFDP1 90758390-90758395 0.99 
TLX2 90757886-90757895 0.85 
ZBTB16 90759660-90759688 0.73 
ZIC1, ZIC2, ZIC3 90758724-90758732 0.49 
ZIC1, ZIC2, ZIC3 90758668-90758676 0.58 
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potential binding sites for transcription factors (Table 11). To clarify whether the 
mRNA levels of these transcription factors are affected by knockdown of GAK, 
the genetically manipulated cultured cortical samples were assayed using the 
Affymetrix GeneChip Rat Gene 2.0 ST arrays and available probes targeting 71 
SNCA transcription factors were assessed for association to GAK expression. 
After FDR adjustment, nine of the seventy-one genes assessed were significantly 
associated with GAK expression with p-value less than 0.05 (Table 12). Of the 
transcription factors that serve as transcriptional activators, four are increased in 
expression upon GAK knockdown, while one transcription factor, which serves as 
an enhancer or repressor depending on the context, is decreased in expression 
upon GAK knockdown. 
 1.7. Knockdown of GAK in Primary Rat Cortical Neurons Alters Expression of 
Known GAK-interacting Genes 
 Finally, in order to validate GAK-interacting genes’ exons associated to 
GAK Gencode exon 25 expression by RNA-seq in human brain tissue (Table 9), 
these same genes were queried using the microarray data obtained from the 
genetically manipulated primary cortical neuronal cultures described above. Of 
the sixteen genes queried, seven were significantly associated (after FDR 
adjustment, p-value less than 0.05) with GAK knockdown, with five of these 
showing the same direction of effect that was observed in the RNA-seq 
association study between those particular genes’ exons and GAK exon 25 
(Table 13). Additionally, of the genes that didn’t reach statistical significance for  
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Table 12. Transcription Factors with Annotated Binding Sites Nearby SNCA 
are Associated with GAK Expression in Primary Cortical Neurons. * = 
potential transcription factors affecting SNCA expression based on their 
relationship to GAK expression and their purported function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene GAK Association β-est
FDR adjusted 
p-value
Transcriptional 
Function
EGR1 0.064 < 0.01 activator
EGR3 0.11 < 0.01 activator
CREB1 0.041 0.018 activator
ELF1 * 0.11 0.023 enhancer/repressor
UBTF * -0.039 0.027 activator
HMGA1 0.065 0.048 activator
NFIX * -0.025 0.048 activator
SPI1 * -0.097 0.048 activator
ZBTB16 * -0.075 0.048 activator
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Table 13. Genes with Gencode Exons Associated to GAK Gencode Exon 25 
Expression in Post-mortem Human Brain Tissue Are Affected by GAK 
Knockdown in Primary Cortical Cultures. The β-est indicates the association 
between GAK expression in the microarray and the expression of the gene of 
interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name Human Ensemble ID Rat Ensembl ID GAK association β-est
FDR adjusted 
p-value
Same Effect 
Direction as 
RNA-seq
CDK5 ENSG00000164885 ENSRNOG00000008017 -0.067 < 0.01 yes
SNCA ENSG00000145335 ENSRNOG00000008656 -0.048 < 0.01 yes
AP1M1 ENSG00000072958 ENSRNOG00000014454 -0.022 < 0.01 yes
SNAP91 ENSG00000065609 ENSRNOG00000023861 -0.017 < 0.01 yes
CREBBP ENSG00000005339 ENSRNOG00000005330 0.039 < 0.01 yes
HIP1 ENSG00000127946 ENSRNOG00000001448 -0.040 0.02 no
USO1 ENSG00000138768 ENSRNOG00000002301 0.026 0.02 no
DNM2 ENSG00000079805 ENSRNOG00000007649 0.015 0.11 yes
NUMB ENSG00000133961 ENSRNOG00000009653 0.019 0.11 no
CLTC ENSG00000141367 ENSRNOG00000004291 0.015 0.20 no
CCNG1 ENSG00000113328 ENSRNOG00000003256 -0.0051 0.30 no
NUMBL ENSG00000105245 ENSRNOG00000020867 -0.0098 0.43 yes
AP2M1 ENSG00000161203 ENSRNOG00000001709 -0.0061 0.45 yes
PSMD2 ENSG00000175166 ENSRNOG00000001719 -0.0046 0.52 yes
HSPA8 ENSG00000109971 ENSRNOG00000009920, 
ENSRNOG00000042071
0.0014 0.84 yes
HIP1R ENSG00000130787 ENSRNOG00000001091 0.0016 0.94 yes
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association to GAK knockdown, more than half showed the same direction of 
association with GAK as that which was observed the RNA-seq study. 
 
2. Differential GAK expression in Parkinson Disease Brain and Primary 
Cortical Neurons Causes Dysregulation of Genes Functioning at the 
Synapse and Mitochondria.  
2.1. Genes Associated with GAK Gencode Exon 25 Expression in Human Brain 
Are Involved in Synaptic Function and Neuronal Development. 
 As presented in the last section, expression in human PD and control 
brain tissue of Gencode exon 25 in GAK, an exon representative of the 
expression of the 3’ exons of GAK, is significantly associated with the expression 
of several genes previously acknowledged to interact with GAK protein, including 
SNCA. In order to elucidate novel pathways in which differential GAK expression 
might play a role, genome-wide association analysis using the RNA-sequencing 
data generated from the samples studied as well as GLM was performed on all 
exons’ expression to GAK exon 25 expression, adjusting for case status, age at 
death, and PMI of the samples. Those exons with FDR-adjusted p-values less 
than 0.05 and mean normalized counts greater than ten were then assessed for 
genic enrichment. There were 871 genes observed to have greater than 50% of 
their exons significantly associated with GAK exon 25 expression, while only 439 
had 75% or greater of their exons significantly associated with GAK expression 
(Table 14). Intriguingly, more than twice as many genes demonstrate significantly  
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Table 14. Genome-wide Exon Analysis Demonstrates Genes with High 
Percentages of their Exons Significantly Associated to GAK Gencode Exon 
25 in Human Brain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Percentage Exons 
Associated
Genes Directly 
Associated
Genes Inversely 
Associated Total
> 50% 244 627 871
> 75% 123 316 439
> 90% 93 238 331
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associated exons inversely related to GAK exon 25 expression than directly 
related to exon 25 expression. 
 In order to determine what role these genes might play in the brain in  
concert with one another and with GAK, those genes with greater than 50% of 
their exons associated with GAK exon 25 expression were assessed for gene 
ontology (GO) term enrichment using the DAVID functional annotation tool. Of 
the 871 Ensembl IDs assessed (corresponding to each of the 871 genes), 629 
were functionally annotated with significant enrichment in pathways relating to 
neuronal/synaptic structure and function and clathrin-coated vesicular trafficking 
(Table 15). Surprisingly, when genes directly associated with GAK exon 25 
expression were assessed, only one GO term (GO:0008092 – cytoskeletal 
protein binding) was observed to be enriched which was different from those 
observed in the full gene set, while genes inversely associated with this exon 
accounted for all the GO term enrichment shown in Table 15. 
 In order to identify novel networks in which these genes function, the 871 
genes associated with GAK exon 25 expression were assessed using IPA. As 
IPA utilizes not only the gene identifiers (in this case Ensembl IDs) but also 
analysis results, the association results for the exons with the most significant 
association (lowest FDR adjusted p-value) for each unique gene were used as 
input for the network analysis. After mapping 692 of these genes to the database, 
network analysis was performed to discover novel pathways containing the 
genes associated with GAK expression levels in PD brain. The top three gene  
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Table 15. Genes Associated with GAK Gencode Exon 25 Expression are 
Significantly Enriched in Pathways Related to Synaptic Structure and 
Function in Human Brain. Gene count indicates the number of genes 
associated with the particular GO term out of 629 genes assessed.  
 
 
 
 
 
 
 
 
 
 
 
 
GO Term Gene Count
Fold 
Enrichment
FDR adjusted 
p-value
GO:0043005~neuron projection 47 4.1 6.2E-13
GO:0007268~synaptic transmission 39 4.1 4.5E-10
GO:0019226~transmission of nerve impulse 40 3.6 1.6E-08
GO:0045202~synapse 41 3.4 2.0E-08
GO:0030424~axon 27 5.1 2.4E-08
GO:0008021~synaptic vesicle 18 7.1 5.3E-07
GO:0007267~cell-cell signaling 50 2.6 2.3E-06
GO:0044456~synapse part 30 3.6 5.0E-06
GO:0006836~neurotransmitter transport 17 6.4 1.1E-05
GO:0042995~cell projection 54 2.3 2.2E-05
GO:0000149~SNARE binding 11 9.5 1.9E-04
GO:0019905~syntaxin binding 10 10.3 4.2E-04
GO:0006091~generation of precursor metabolites and energy 30 3.0 4.7E-04
GO:0030136~clathrin-coated vesicle 19 4.3 5.6E-04
GO:0030672~synaptic vesicle membrane 9 11.7 6.5E-04
GO:0031982~vesicle 49 2.2 6.7E-04
GO:0031410~cytoplasmic vesicle 47 2.2 1.2E-03
GO:0030135~coated vesicle 20 3.7 2.1E-03
GO:0043025~cell soma 20 3.5 4.9E-03
GO:0006811~ion transport 49 2.0 0.011
GO:0005516~calmodulin binding 17 3.9 0.011
GO:0030665~clathrin coated vesicle membrane 11 6.2 0.012
GO:0048489~synaptic vesicle transport 9 8.5 0.012
GO:0006812~cation transport 39 2.2 0.013
GO:0001505~regulation of neurotransmitter levels 12 5.6 0.014
GO:0030054~cell junction 38 2.2 0.016
GO:0032940~secretion by cell 21 3.2 0.019
GO:0015672~monovalent inorganic cation transport 27 2.7 0.020
GO:0007611~learning or memory 15 4.2 0.020
GO:0031988~membrane-bounded vesicle 40 2.1 0.023
GO:0016023~cytoplasmic membrane-bounded vesicle 39 2.1 0.026
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networks identified from this analysis are involved in cell-to-cell signaling and 
interaction (Figure 7), nervous system development and function (Figure 8), and 
neurological disease and psychological disorder (Figure 9), which mirror the 
results obtained from DAVID analysis of these genes. 
2.2. Genes Associated with GAK Expression in Cultured Cortical Neurons are 
Involved in Synaptic and Mitochondrial Function and Developmental Pathways. 
 While association analyses in human brain between GAK Gencode exon 
25 expression and genome-wide exon expression reveal intriguing new pathways 
not previously attributed to GAK, the underlying biological cause for these 
associations is unclear. In order to model and validate the GAK association 
observations described in post-mortem human tissue, a GAK knockdown and 
SNCA over-expression model in primary rat cortical neurons was developed. A 
panel of four shRNA’s targeting GAK was initially tested for optimal knockdown of 
the gene in the rat cell line PC-12. As determined by qRT-PCR and Western Blot 
analysis, the shRNA construct B produced the greatest extent of knockdown in 
these cells, targeting RefSeq exon 5 in rat GAK (Figure 10).  
 Lentiviral particles containing the shRNA constructs (B and negative 
control) as well as particles containing constructs for the overexpression of WT 
human SNCA cDNA (as well as a ZsGreen fluorescent protein positive control) 
were co-infected into seven DIV primary rat cortical neurons derived from 
embryonic day 18 rat fetuses. Protein and mRNA were extracted from these cells 
96 hours after transduction, and GAK knockdown and SNCA over-expression 
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Figure 7. IPA Network Analysis Reveals Genes Involved in Cell-to-Cell 
Signaling and Interaction as Associated to GAK Gencode Exon 25 
Expression in Human Brain. Nodes highlighted in red indicate genes directly 
associated with GAK exon 25 expression, while those in green indicate genes 
inversely associated. Darker shades of these colors indicate greater association 
of the nodes to GAK exon 25 expression. Nodes with no color denote genes 
which complete connectivity between other nodes but were not significantly 
associated with GAK exon 25 expression. 
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Figure 8. IPA Network Analysis Reveals Genes Involved in Nervous System 
Development and Function as Associated to GAK Gencode Exon 25 
Expression in Human Brain. Nodes highlighted in red indicate genes directly 
associated with GAK exon 25 expression, while those in green indicate genes 
inversely associated. Darker shades of these colors indicate greater association 
of the nodes to GAK exon 25 expression. Nodes with no color denote genes 
which complete connectivity between other nodes but were not significantly 
associated with GAK exon 25 expression. 
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Figure 9. IPA Network Analysis Reveals Genes Involved in Neurological 
Disease and Psychological Disorder as Associated to GAK Gencode Exon 
25 Expression in Human Brain. Nodes highlighted in red indicate genes directly 
associated with GAK exon 25 expression, while those in green indicate genes 
inversely associated. Darker shades of these colors indicate greater association 
of the nodes to GAK exon 25 expression. Nodes with no color denote genes 
which complete connectivity between other nodes but were not significantly 
associated with GAK exon 25 expression. 
 
 
 
 
 
 
 
 
 76 
 
 
Figure 10. Testing of Various Lentiviral shRNA Constructs for GAK 
Knockdown Efficiency by qRT-PCR and Western Blotting in PC-12 Cells. 
PC-12 cells were transiently transfected with each lentiviral shRNA construct 
targeting GAK (A-D), as well as the control negative shRNA (Cont). An 
untransfected well was also assessed for GAK mRNA and protein levels. (A) As 
measured by qRT-PCR using Taqman Assay Rn01638195_m1, constructs A and 
B produce an approximately 50% reduction in GAK mRNA expression as 
compared to the Control shRNA. (B) As measured by Western Blot, construct B 
produces an approximately 50% reduction in GAK protein expression. 
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were assessed by qRT-PCR and Western Blotting. As described in Results 
Section 1.4, GAK-targeting shRNA resulted in a 50% reduction in GAK mRNA 
expression in these neurons (Figures 5A), while expression of the human  
SNCA cDNA increased expression of SNCA 3-5 fold over endogenous levels of 
rat SNCA (Figure 5B). 
 The mRNA derived from these neurons was then assayed for genome-
wide expression using the Affymetrix GeneChip Rat Gene 2.0 ST array. The raw 
intensities from the probes were assessed for quality across all twelve samples 
using Relative Log Expression (RLE) and Normalized Unscaled Standard Error 
(NUSE) analyses; all of the samples assessed were observed to have good 
sample quality and similar cellular profiles based on these metrics (Figure 11).  
 The samples were then normalized using the robust multi-array average 
(RMA) method, and principle components analysis (PCA) was performed to 
understand the uncorrelated variances among the samples. Those samples in 
which GAK was knocked down showed strong segregation along the first 
principle component (PC1) from those samples in which negative control shRNA 
was transduced (Figure 12). Of those samples in which GAK expression was 
knocked down, there is segregation along the second principle component (PC2) 
between samples in which SNCA was also over-expressed as compared to 
samples in which ZsGreen was over-expressed (Figure 12). Samples that were 
transduced with the negative control shRNA and in which SNCA was over-
expressed or ZsGreen was over-expressed showed no segregation from one  
 78 
 
 
Figure 11. Quality Control Assessment of Microarray-Assayed Cultured 
Cortical Samples. (A) The distribution of Relative Log Expression (RLE) is 
shown for each sample by boxplot. Samples with median RLE’s no greater than 
±0.5 are considered to have good quality data; the horizontal line within each 
boxplot for each sample indicates median value. (B) The distribution of 
Normalized Unscaled Standard Error (NUSE) is shown for each sample by 
boxplot. Samples with median NUSE’s no greater than 1±0.05 are considered to 
have good quality data; the horizontal line within each boxplot for each sample 
indicates median value. 
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Figure 12. Principle Component Analysis of Microarray Data Reveals 
Strong Clustering of Samples by GAK Knockdown. The four conditions 
analyzed (with three samples per condition) are indicated in the legend: Over-
expression of ZsGreen with negative control shRNA (ZsGreen OE, Cont shRNA); 
Over-expression of ZsGreen with GAK-targeted shRNA (ZsGreen OE, GAK KD); 
Over-expression of SNCA with negative control shRNA (WTsyn OE, Cont 
shRNA); and Over-expression of SNCA with GAK-targeted shRNA (WTsyn OE, 
GAK KD). PC1 and PC2 indicate the first and second principle components, 
respectively. 
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another. 
 Next, each of the conditions was assessed in pair-wise contrasts to one 
another for genome-wide differential expression using a linear regression  
approach and empirical Bayes statistics. After adjusting for multiple  
comparisons, differentially expressed probesets were only observed between 
GAK and negative control shRNA-transduced conditions; no genome-wide 
significant differences were observed between SNCA and ZsGreen over-
expressed conditions. In the presence of over-expressed ZsGreen, GAK 
knockdown resulted in 591 up-regulated genes and 635 down-regulated genes 
as compared to negative control shRNA; however, in the presence of over-
expressed SNCA, the knockdown of GAK caused only 146 genes to be up-
regulated and 127 genes to be down-regulated as compared to the negative 
control (Figure 13). Interestingly, several differentially expressed genes were 
common to both contrasts (72 up-regulated, 90 down-regulated), and two genes, 
CALU and BSCL2 were observed to be differentially expressed in both contrasts 
but in opposite directions between the two. 
 As the pair-wise contrasts between conditions reveal, many genes appear 
to be expressed differently in comparisons where GAK has been knocked down 
or not depending on whether SNCA or ZsGreen are also co-expressed. In order 
to understand the overall effect of GAK knockdown in the context of over-
expressed ZsGreen or SNCA, a multivariable generalized linear regression 
analysis was utilized whereby all genes’ expression were assessed for their  
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Figure 13. Comparisons of Differentially Expressed Genes in Common and 
Different in Contrasts of GAK and Negative Control shRNA-Transduced 
Cells. The contrasts differ by whether WT SNCA (WTSYN) or ZsGreen are co-
expressed with the respective shRNAs. Total numbers of up-regulated (green in 
color) and down-regulated (red in color) genes in common and different between 
the contrasts are indicated within the particular portions of the venn diagram. 
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relationship to GAK expression adjusted for whether SNCA was also co-
expressed (as a binomial trait). In total, 2,014 genes were observed to be 
associated with GAK expression in all samples after FDR adjustment; of these, 
392 were also nominally associated with SNCA over-expression.  
 In order to gain insight into the functional role that genes affected by GAK 
knockdown play in cortical neurons, GO term enrichment was assessed using 
the 2,014 genes found to be associated with GAK knockdown in the multivariable 
linear regression analysis utilizing the DAVID annotation tool. The Ensembl IDs 
corresponding to each gene were utilized for the analysis, and 1,797 of the 
genes assessed were functionally annotated, with significant enrichment for GO 
terms related to synaptic and mitochondrial structure and function (Table 16). 
When just those 392 genes genome-wide associated to GAK expression and 
also nominally associated to SNCA expression were assessed using DAVID, 363 
were functionally annotated and only three GO terms were significantly enriched, 
all being involved with mitochondrial structure (GO:0005739, GO:0044429, and 
GO:0031967). 
 The genes associated with GAK expression in the microarray study were 
next assessed for networks in which they function using IPA. Again, input for IPA 
not only included Ensembl gene ID’s but also the respective beta coefficients and 
FDR-adjusted p-values from the linear regression analysis for association to GAK 
expression. In total, 1,843 genes were mapped to the database, and these genes 
were overlaid on key networks related to cancer biology (Figure 14), DNA  
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Table 16. Genes Associated with GAK Expression are Significantly 
Enriched in Pathways Related to Synaptic and Mitochondrial Structure and 
Function. Gene count indicates the number of genes associated with the 
particular GO term out of 1,797 genes assessed. 
 
 
GO Term Gene Count
Fold 
Enrichment
FDR adjusted 
p-value
GO:0045202~synapse 76 2.2 3.4E-08
GO:0005739~mitochondrion 177 1.6 1.9E-07
GO:0031410~cytoplasmic vesicle 100 1.9 7.4E-07
GO:0044456~synapse part 56 2.4 1.2E-06
GO:0043005~neuron projection 79 2.0 2.1E-06
GO:0031988~membrane-bounded vesicle 92 1.9 2.7E-06
GO:0016023~cytoplasmic membrane-bounded vesicle 89 1.9 3.1E-06
GO:0031982~vesicle 102 1.8 4.4E-06
GO:0032553~ribonucleotide binding 194 1.5 2.9E-05
GO:0017076~purine nucleotide binding 201 1.4 3.6E-05
GO:0032555~purine ribonucleotide binding 193 1.5 4.1E-05
GO:0044429~mitochondrial part 85 1.8 4.2E-05
GO:0043167~ion binding 325 1.3 6.8E-05
GO:0031090~organelle membrane 133 1.6 7.4E-05
GO:0046872~metal ion binding 314 1.3 2.0E-04
GO:0031967~organelle envelope 86 1.8 3.2E-04
GO:0043169~cation binding 316 1.3 3.7E-04
GO:0031975~envelope 86 1.7 4.4E-04
GO:0042995~cell projection 106 1.6 5.0E-04
GO:0000166~nucleotide binding 226 1.4 6.6E-04
GO:0007611~learning or memory 32 2.7 7.8E-04
GO:0019717~synaptosome 27 2.8 2.1E-03
GO:0005740~mitochondrial envelope 64 1.8 2.6E-03
GO:0007268~synaptic transmission 43 2.2 2.9E-03
GO:0005886~plasma membrane 273 1.3 4.2E-03
GO:0008021~synaptic vesicle 22 3.1 5.5E-03
GO:0030424~axon 39 2.2 6.0E-03
GO:0031974~membrane-enclosed lumen 158 1.4 6.0E-03
GO:0007610~behavior 67 1.8 9.5E-03
GO:0030030~cell projection organization 59 1.8 0.014
GO:0001883~purine nucleoside binding 162 1.4 0.014
GO:0001882~nucleoside binding 163 1.4 0.015
GO:0030554~adenyl nucleotide binding 159 1.4 0.018
GO:0032559~adenyl ribonucleotide binding 151 1.4 0.023
GO:0007612~learning 20 3.1 0.023
GO:0031966~mitochondrial membrane 58 1.8 0.023
GO:0005624~membrane fraction 98 1.5 0.023
GO:0005626~insoluble fraction 102 1.5 0.026
GO:0012505~endomembrane system 89 1.6 0.031
GO:0048666~neuron development 56 1.8 0.035
GO:0015179~L-amino acid transmembrane transporter activity 13 4.2 0.041
GO:0044459~plasma membrane part 164 1.3 0.041
GO:0043233~organelle lumen 150 1.4 0.043
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Figure 14. IPA Network Analysis Reveals Genes Involved in Cancer Biology 
as Associated to GAK Expression in Cultured Cortical Neurons. Nodes 
highlighted in red indicate genes directly associated with GAK expression, while 
those in green indicate genes inversely associated. Darker shades of these 
colors indicate greater association of the nodes to GAK expression. Nodes with 
no color denote genes which complete connectivity between other nodes but 
were not significantly associated with GAK expression. 
 85 
 
 
Figure 15. IPA Network Analysis Reveals Genes Involved in DNA replication 
and Cell Proliferation as Associated to GAK Expression in Cultured 
Cortical Neurons. Nodes highlighted in red indicate genes directly associated 
with GAK expression, while those in green indicate genes inversely associated. 
Darker shades of these colors indicate greater association of the nodes to GAK 
expression. Nodes with no color denote genes which complete connectivity 
between other nodes but were not significantly associated with GAK expression. 
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Figure 16. IPA Network Analysis Reveals Genes Involved in Embryonic and 
Nervous System Development as Associated to GAK Expression in 
Cultured Cortical Neurons. Nodes highlighted in red indicate genes directly 
associated with GAK expression, while those in green indicate genes inversely 
associated. Darker shades of these colors indicate greater association of the 
nodes to GAK expression. Nodes with no color denote genes which complete 
connectivity between other nodes but were not significantly associated with GAK 
expression. 
 
 
 
 87 
replication and cell proliferation (Figure 15), and embryonic and nervous system 
development (Figure 16).  
2.3. Genes Associated with GAK Expression in Both Post-Mortem Brain and 
Cultured Neurons are Associated with Neurological Disease and Synaptic 
Function. 
 As the results from the RNA-sequencing and Microarray analysis 
demonstrate, many genes are associated with and respond to differential GAK 
expression in different biological contexts, which give rise to the variation 
observed in the previously performed pathway analyses. In order to understand 
the common key pathways in which GAK plays a fundamental role, the genes 
found to have at least 50% of their exons associated to GAK Gencode exon 25 in 
human brain were compared to the genes differentially expressed after GAK 
knockdown in cultured cortical neurons. In total, 126 genes were observed to be 
significantly associated to GAK expression in both analyses; however, only 91 of 
them were associated with GAK in the same direction in both analyses. 
 Using DAVID analysis, 87 genes of the 91 with the same direction of effect 
in both data sets were functionally annotated, and enrichment for GO terms 
related to synaptic transmission was observed from this gene set (Table 17). 
Next, the 91 genes were analyzed for common networks in which they play a role 
using IPA. After mapping all input genes, gene networks associated with 
neurological disease (Figure 17) and with cell-to-cell signaling (Figure 18) were  
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Table 17. Common Genes Associated with GAK Expression in PD brain and 
in Cultured Neurons are Significantly Enriched in Pathways Related to 
Synaptic Transmission. Gene count indicates the number of genes associated 
with the particular GO term out of 87 genes assessed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GO Term Gene Count Fold Enrichment
FDR adjusted 
p-value
GO:0045202~synapse 12 6.4 2.2E-03
GO:0007268~synaptic transmission 10 6.3 0.038
GO:0044456~synapse part 9 7.0 0.045
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Figure 17. IPA Network Analysis Reveals Genes Involved in Neurological 
Disease as Associated to Both GAK Gencode Exon 25 in Human PD Brain 
and GAK Expression in Cultured Cortical Neurons. Nodes highlighted in red 
indicate genes directly associated with GAK expression, while those in green 
indicate genes inversely associated. Darker shades of these colors indicate 
greater association of the nodes to GAK expression. Nodes with no color denote 
genes which complete connectivity between other nodes but were not 
significantly associated with GAK expression. 
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Figure 18. IPA Network Analysis Reveals Genes Involved in Cell-to-Cell 
Signaling as Associated to Both GAK Gencode Exon 25 in Human PD Brain 
and GAK Expression in Cultured Cortical Neurons. Nodes highlighted in red 
indicate genes directly associated with GAK expression, while those in green 
indicate genes inversely associated. Darker shades of these colors indicate 
greater association of the nodes to GAK expression. Nodes with no color denote 
genes which complete connectivity between other nodes but were not 
significantly associated with GAK expression. 
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identified, corresponding to similar networks identified from the just the RNA-
sequencing study alone. 
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CHAPTER FOUR – DISCUSSION 
1. Decreased GAK Expression is Associated with 4p16.3 PD Risk SNPs and 
Increased expression of SNCA. 
 Using an agnostic region-wide approach, we found PD GWAS SNP risk 
alleles in the 4p16.3 region to be associated with significantly decreased 
expression of the Gencode defined exon 25 (p=5.9x10-5) of the GAK gene 
(GAK25), which in turn is inversely associated with SNCA exon expression. This 
inverse relationship was validated in primary cortical neurons where GAK 
expression was knocked down, resulting in increased endogenous SNCA 
expression, presumably through transcriptional activation of the SNCA locus. 
Additionally, exons in the 3’ region of GAK were increased in expression in PD as 
compared to controls in human prefrontal cortical brain tissue. Finally, we 
observed strong associations between GAK25 and the expression of several 
genes known to interact with GAK protein, suggesting co-regulation of these 
genes’ expression in cortical tissue. Together, these results support the 
attribution of the observed PD GWAS signal at 4p16.3 to GAK alone and provide 
novel interactions and roles for this protein in the pathogenesis of PD. 
 As the results demonstrate, exons in the 3’ region of GAK are increased in 
expression in PD as compared to controls in prefrontal human brain tissue. 
Interestingly, the Gencode project has identified several protein-coding 
alternative short transcripts in the 3’ region of GAK, including one that utilizes 
GAK Gencode exon 25 (hereafter referred to as GAK25) as the 5’ UTR  
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Figure 19. GAK Exons Significantly Associated to Case Status Primarily 
Encode for the Clathrin-Binding and J Domains of GAK protein. GAK Exon 
25 (GAK25), which was found to be associated to both Case Status and the Risk 
SNP, is highlighted in magenta. All Gencode transcripts are shown within the 
shaded boxes, with transcript functionality listed below each contig. The GAK 
protein domains are denoted by color: J domain (green), clathrin-binding domain 
(yellow), phosphatase/tensin domain (blue), and kinase domain (red).  
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(Transcript 009, Figure 19). As GAK25 is unique to this single transcript, we can 
postulate that this transcript is uniquely increased in expression in PD. 
Furthermore, GAK25 is highly correlated to the expression of other 3’ exons in 
GAK, and as many of these other 3’ exons are expressed in higher amounts 
relative to GAK25, this suggests the other 3’ truncated transcripts are also 
increased in PD. Because these smaller transcripts translate to form protein 
containing only the clathrin-binding and J domains of GAK, it appears these 
abbreviated proteins (009, 010, and 011 in Figure 19) may have an important 
role in mitigating the effect of the disease through the function of these domains 
in facilitating clathrin-mediated endocytosis44,53,54,56.  
 The exons in the 5’ region of the gene show little to no association to PD, 
which indicates the 5’ abbreviated transcripts (003, 007, and 014 through 023 in 
Figure 19) as well as the full-length transcripts (001 and 002 in Figure 19) of GAK 
may have little functional relevance in the context of PD. The 5’ portion of GAK 
encodes the kinase and phosphatase/tensin domains of the protein, suggesting a 
limited role for these functions in the context of PD. Because the full-length 
transcripts encompass both the 5’ and 3’ portions of the gene, and no significant 
association was observed in the 5’ exons, it is possible that stronger association 
to case status was not observed for the 3’ exons due to an overall masking effect 
by these longer transcripts. 
 When stratified by risk SNP rs1564282 carrier status, homozygote major 
allele carriers with PD showed significantly increased expression of the 3’ exons 
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as compared to control major allele homozygotes. However, minor allele carriers 
with PD showed no significant increase in expression for many of these same 
exons as compared to control minor allele carriers, suggesting an abrogating 
effect of the minor allele of the risk SNP on expression. When both case status 
and the risk SNP (modeled additively) were used to predict exon expression in a 
multivariable analysis, several exons showed increased expression in PD as 
compared to controls, but had nominally decreased differential expression in risk 
SNP minor allele carriers when compared to major allele homozygotes, with 
GAK25 showing significance to both case status and the risk SNP after FDR 
adjustment. As the minor allele of the risk SNP has been shown to increase the 
risk for PD, we hypothesize that the relationship of the SNP to reduced exon 
expression may represent a compromise of what we believe to be an adaptive 
and potentially protective response of the abbreviated 3’ transcripts of GAK to the 
disease. The observation that the risk SNP is associated with decreased GAK 
expression consequently provided the impetus to study the effect of decreased 
GAK expression by genetic knockdown in a neuronal cellular model with and 
without SNCA over-expression. 
 As discussed earlier, several SNPs in this region have been reported to be 
associated to PD risk42,70-73,76,98, with all of them in high linkage disequilibrium 
(LD) with one another. However, identifying which one of these SNPs functions 
to down-regulate the expression of the 3’ exons in GAK remains elusive. 
Theoretically, SNPs nearby to transcription factor binding sites upstream of these 
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short transcripts might reduce transcription factor binding, thus reducing overall 
expression of these small GAK transcripts; this regulatory effect has been 
demonstrated for a number of other cellular systems and disease phenotypes99-
106.  
 Likewise, if a SNP falls near a key regulatory site involved in the 
processing of the mRNA to form a mature transcript, it may cause dysfunctional 
processing and thus premature decay of the mRNA or respective protein product. 
Indeed, SNPs identified in the GAK homolog DNAJC6 have been shown to 
cause mis-splicing events in the gene, leading to decreased mRNA expression 
and the onset of juvenile parkinsonism81. In unpublished findings, the Myers lab 
sequenced and identified several SNPs in the 3’ region of GAK that were in high 
LD with the risk SNP, with one, rs55728587, falling at a splice junction regulatory 
site in the last intron of the gene. While this splice site may be a candidate to 
explain the mechanism of down-regulation of these shorter 3’ GAK transcripts, 
greater in-depth sequencing of the intronic region upstream of these transcripts is 
needed to understand if there is also transcriptional dysregulation of these 
shorter transcripts by aberrant transcription factor binding. 
 GAK25 expression was shown to be associated with the expression of 
exons in a number of genes known to functionally interact with GAK at the 
protein level as annotated by STRING (Table 9). Perhaps unsurprisingly, many of 
the genes showing the strongest associations are involved with GAK in clathrin-
coated vesicle formation and endocytosis at the plasma membrane. 
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SNAP91/AP180 and AP2 protein (a subunit of which is encoded by AP2M1) play 
a role in assembling the clathrin tri-skelelia on the invaginating pits during 
endocytosis and in recruiting specific receptors to these pits58,107-119, while HIP1 
appears to interact directly with AP2 and clathrin as part of the endocytotic 
machinery120,121 and the GTPase Dynamin 2 (encoded by DNM2) is responsible 
for the scission of these newly formed vesicles from the membranes after 
endocytosis122-124. However, in context with the association of GAK25 to exons in 
SNCA, which has been shown to function at the synapse6-20, these relationships 
suggest specific GAK function in clathrin-mediated endocytotic events at the 
synapse in human brain and cortical neuronal cultures. 
 Several proteins with prior evidence for a role in Parkinson Disease, 
including ATP13A2, Cathepsin D and LRRK2, have demonstrated interaction 
with the GAK protein60,65,79, but were not included in the STRING analysis for 
GAK interactors as their confidence score was below the minimum threshold at 
0.4, which is deemed medium confidence for interaction by the algorithm. LRRK2 
was assessed in the STRING analysis for SNCA interactors, but the exons in 
LRRK2 associated to GAK were in opposite directions from one another, 
suggesting various transcripts of LRRK2 may be differently related to GAK 
expression. In unbiased genome-wide analyses for association to GAK, the 
exons of ATP13A2 and CTSD showed little association to GAK25 in PD brain, 
and their microarray expression showed no association to GAK expression in 
cortical neurons upon GAK knockdown (Results Section 2). While these results 
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do not preclude important interactions between GAK protein and ATP13A2 or 
Cathepsin D proteins that may affect PD pathogenesis, strong mRNA interaction 
between these genes and GAK does not seem evident.    
 It remains unclear whether differential expression of SNAP91, AP2M1, 
HIP1, DNM2 and SNCA exon expression under conditions of decreased GAK 
expression (as in the case of GAK risk SNP carriers in human brain or shRNA-
mediated knockdown in cortical neuronal cultures) denotes merely a 
compensatory mechanism for dysfunctional endocytosis at the synapse or a 
pathway leading to pathogenic accumulation of α-synuclein. As was mentioned 
earlier, knockdown of GAK in cultured non-neuronal cells has been shown to 
affect clathrin-coated pit formation and AP2 protein association to the plasma 
membrane leading to detrimental effects on endocytosis53,56; therefore, it is 
reasonable to suggest a similar effect in neuronal cells and an attempt by the 
neuron to correct for this impairment by altering the expression of these genes. 
However, the increased endogenous SNCA expression upon GAK reduction in 
PD brain and cultured cortical neurons may indicate a potential novel pathway to 
pathogenesis in PD. Indeed, GAK knockdown in the presence of over-expressed 
α-synuclein protein was shown to cause increased toxicity in HEK293 cells and 
TH+ midbrain neurons78. These findings, coupled with the data presented here, 
suggest that other genes associated with GAK reduction may instead play a role 
in this increased toxicity. In order to dissect these two potential outcomes from 
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one another, further study of the effects of reduced GAK expression in neuronal 
culture and animal models is warranted. 
 Identification of the transcriptional regulators responsible for the increased 
SNCA expression associated with reduced GAK expression in PD brains and 
caused by shRNA-mediated knockdown of GAK in cortical neurons can provide 
insight on pathogenic pathways in PD and potential therapeutic targets to treat 
the disease. Based on annotated transcription factor binding site motifs nearby to 
SNCA as profiled using the Swissregulon database and gene microarray 
expression data, several transcription factors were identified, including ZBTB16, 
NFIX, and ELF1, which were differentially expressed upon GAK knockdown and 
could potentially cause increased SNCA expression. The PLZF transcription 
factor, encoded by ZBTB16, interacts with GATA transcription factors known to 
up-regulate SNCA expression125-128, while the transcription factors encoded by 
NFIX and ELF1 are important in neuronal development129-135.  
 Still, other transcription factors, not differentially expressed at the mRNA 
level, may have been activated by other means, including mitogen-activated 
phosphorylation cascades and direct protein-protein interaction. Indeed, previous 
studies have identified promoter site response elements important in SNCA 
transcriptional regulation during differentiation and have implicated the 
transcription factors ZSCAN21 and ZNF219 as well as the Phosphoinositide 3-
kinase signaling cascade in mediating this regulation136-138. GAK knockdown has 
been shown to alter the membrane localization of several phosphorylation 
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cascade-activating membrane receptors, including Epithelial Growth Factor 
Receptor, Transferrin Receptor, Notch Receptor and Insulin Growth Factor 
Receptor53,67,139,140. Hence, in pursuit of an upstream therapeutic target that 
might affect SNCA expression, in depth mechanistic analysis of transcription 
factor binding to the SNCA locus in the context of GAK knockdown is required. 
 In summary, prefrontal cortical expression of exons in the 3’ region of GAK 
are associated not only with PD and the risk SNP rs1564282, but also with the 
expression of several genes whose protein products are known to functionally 
interact with the GAK protein, including SNCA. While GAK knockdown has been 
previously shown to increase levels of over-expressed α-synuclein in the 
HEK293 cell line, these results demonstrate unequivocal up-regulation of SNCA 
mRNA expression upon GAK expression reduction in PD brain and cultured 
cortical neurons, providing a novel mechanism to pathogenesis of PD. 
 
2. Differential GAK expression in Parkinson Disease Brain and Primary 
Cortical Neurons Causes Dysregulation of Genes Functioning at the 
Synapse and Mitochondria.  
 While several studies have demonstrated GAK’s function during mitosis48-
51 and clathrin-mediated endocytosis44,52-56, no study to date has used an 
unbiased genome-wide approach to understand its function and pathways in 
which it plays a role, particularly in neurons. Therefore, this genome-wide study 
using RNA-sequence data derived from post-mortem cortical tissue and 
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microarray data derived from cultured cortical neurons depleted of GAK aimed to 
understand pathways and networks in which GAK participates, specifically in the 
context of Parkinson Disease. 
 Centered on findings that 3’ exons in GAK are associated with PD and the 
risk SNP rs1564282, GAK25 was assessed for genome-wide exon association in 
PD brain. Based on pathway analysis and functional annotation of the genes with 
high percentages of their exons associated to GAK (Table 15), GAK appears to 
have a significant relationship to synaptic structure and function in the context of 
PD. As clathrin-mediated endocytosis plays a crucial role at the pre-synaptic 
terminal in recycling vesicles and at the post-synaptic terminal in regulating 
receptor signaling, we hypothesized that GAK might be associated with genes 
functionally annotated with this function. However, the associated genes were 
more significantly enriched for GO terms related to neuronal projections and 
synaptic transmission, and formed gene networks functioning in cell-to-cell 
signaling and neuronal development. Certainly, synaptic function has been 
previously observed in many studies to be negatively affected in PD141-143; 
nonetheless, these findings suggest GAK may play a part in maintaining function 
of these networks, with dysfunctional synaptic function occurring concurrently 
with GAK differential expression in PD. 
 Several of the genes showing association to GAK expression in PD brain, 
which contribute to the GO term enrichment for synaptic function (Table 15), 
have prior evidence for association to PD. Synaptotagmins-4 and -7 (encoded by 
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SYT4 and SYT7) have been shown, in concert with voltage-gated calcium 
channels, to regulate somatodendritic dopamine release144, while synaptotagmin-
1 RNA (encoded by SYT1) has been predicted to potentially co-aggregate with α-
synuclein protein145. Still other GAK-associated genes involved in pre-synaptic 
vesicle formation and release, including STX1A (syntaxin-1), SNAP25 (SNAP-25), 
and SYP (synaptophysin), show evidence for dysregulation in PD and, in the 
case of synaptophysin, co-localization with LB inclusions in PD brains146-152. 
These significant associations lend credence to the hypothesis that GAK 
participates in important synaptic functions, and its differential expression may 
compound any dysfunction already present at the neuronal synapse in PD. 
 The IPA networks identified that contain GAK-associated genes 
discovered from the human brain data support a role for GAK in intercellular 
signaling, neurodevelopment, and neurodegenerative disease. Because these 
networks include genes not only associated with GAK expression, but also 
upstream regulators of the associated genes that may not be associated with 
GAK, it may insinuate non-transcriptomic changes under GAK’s regulation, 
including protein translation and post-translational modification. Several of these 
genes, including MAPT, BDNF, and HTT, have demonstrated roles in 
development and neurodegenerative disease153-156, providing confirmation for 
GAK’s importance in the context of normal neurodevelopment and in PD 
pathogenesis. 
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 In an attempt to model associations between differentially-expressed GAK 
and other genes in the context of Parkinson Disease, cultured cortical neurons 
were depleted of GAK via shRNA-mediated RNAi while also being challenged 
with over-expressed SNCA. Over-expression of α-synuclein in vitro and in vivo 
has long been utilized to understand Parkinson Disease pathogenesis9,24,78,157-164 
and mirrors genetic forms of PD whereby the SNCA gene has been amplified29,30. 
As the combined effect of over-expressed α-synuclein and GAK knockdown on 
the cortical transcriptome has never before been assessed, the cortical culture 
model is not only useful for validating associations observed in the human data 
but also in identifying whether GAK differential expression is responsible for 
these observed transcriptomic changes. 
 Two thousand fourteen genes were observed to be genome-wide 
significantly differentially expressed when GAK expression was reduced in 
cortical neurons (controlling for SNCA over-expression), demonstrating GAK’s 
dramatic influence on transcriptomic regulation. Over-expression of SNCA in 
these same neurons did not result in genome-wide significant differential gene 
expression, but many genes were nominally associated, including 392 which 
were nominally associated to the over-expressed SNCA and genome-wide 
associated to GAK knockdown. As SNCA over-expression has been shown to 
affect proteasome function and mitochondrial sensitivity24,159,161, these subtle 
transcriptomic changes nominally associated with over-expressed SNCA may 
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reflect protein alterations resulting in significant mitochondrial or proteasomal 
phenotypes. 
  GO term enrichment analysis of the genes associated with GAK 
expression in cortical neurons demonstrates a role for GAK not only in synaptic 
and vesicular function, but also in mitochondrial function, which was not 
observed in the human brain data (Table 16). Several of the observed genes play 
a key role in the mitochondrial electron transport chain, including several 
subunits of the NADH dehydrogenase (NDUFA12, NDUFA8, NDUFA9, NDUFB6, 
NDUFB7, NDUFC2, NDUFS1, NDUFS8, AND NDUFV1) and some subunits of 
the ATP-synthase (ATP5O, ATP5J2, and ATP5J). Two other genes increased 
upon GAK knockdown, SIRT3 and SIRT5, encode for the sirtuin-3 and -5 
proteins, which have been shown to have regulatory roles at the mitochondria165-
174 and may have important protective function in the context of 
neurodegenerative disease175-177. As these genes and others are differentially 
expressed in these cultured cortical neurons, it may indicate a compensatory 
cellular response under circumstances of cellular stress and toxicity observed 
when SNCA is over-expressed and GAK expression is depleted78. 
 While IPA networks identified from the GAK knockdown study showed 
evidence for a role for GAK in neurodevelopment as was seen from the PD brain 
data, gene networks involved in cancer biology, cell proliferation, and DNA 
replication were also associated with GAK knockdown. These networks may 
reflect the observed role that GAK plays in mitosis48-51 as well as in cancer 
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progression140,178. Interestingly, these findings were unexpected in this context, 
as the neurons were fully differentiated upon genetic manipulation in order to 
investigate effects that would be observed in mature neurons as were studied in 
the human brain samples. Nevertheless, the evidence for a role for GAK in 
neurodevelopment is strengthened from this network analyses in cortical neurons, 
as well as from the network analysis in post-mortem brain tissue and the 
observation of neurodevelopmental deficits in brain-specific GAK knockout 
animal models66,67. 
 When genes significantly associated to GAK and with similar direction of 
effect in both PD brain and in the cortical neuronal model were assessed for 
gene function, the only GO terms observed to be enriched were related to 
synaptic function (Table 17). The genes responsible for this enrichment were all 
inversely related to GAK expression in both PD brain and the cultured cortical 
neurons in which GAK was knocked down. Intriguingly, these genes encode for 
several gamma-aminobutyric acid receptors (GABRG2 and GABBR2), as well as 
the muscarinic cholinergic receptor 1 (CHRM1), which are important inhibitory 
and excitatory synaptic receptors implicated in PD pathogenesis179-185. Two other 
GAK-associated genes in both PD brain and the cortical neurons, SYN2 
(encoding synapsin-2) and RAB3A (encoding Rab3a) regulate pre-synaptic 
vesicle release186-189, which is impaired by aggregated α-synuclein16,18,20,148,190. 
Together, these results implicate GAK down-regulation in PD as having dramatic 
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negative effects at the synapse, especially when combined with dysregulated α-
synuclein. 
 
3. Final Conclusions 
 In conclusion, while expression of the 3’ region of GAK is increased in PD 
brains, the expression of GAK25 is decreased in risk allele carriers of the 4p16.3 
GWAS risk SNP. The expression of GAK25 is associated with a number of 
known GAK-interactors, including SNCA, and with many different genes not 
previously linked to GAK, which appear to primarily play a role in synaptic 
transmission. The knockdown of GAK in cortical neurons as a model system for 
the effects seen in PD brain also has dramatic effects on the transcriptome, 
resulting in increased SNCA mRNA expression and alterations in genes 
functioning at the synapse and mitochondria. As the number of genes affected by 
altered GAK expression is exceptionally large, and the functional role these 
genes have are common between the two model systems, their dysregulation 
implicates GAK’s important function in transcriptional regulation and synaptic 
transmission in human brain (Figure 20). The dysfunctional regulation of GAK in 
those PD patients who carry the 4p16.3 GWAS risk variant appears to alter these 
two cellular systems in concert with one another, drastically affecting the 
neuron’s ability to function properly both transcriptionally and at the synapse, 
especially while under the burden of the aggregate α-synuclein protein and other 
pathogenicities commonly associated with PD (Figure 21).  
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Figure 20. The Function of GAK in Neurons During Homeostasis. A. 
Activation of trans-membrane receptors at the plasma membrane (1) induces 
signaling cascades mediated by many other proteins that result in the 
transcriptional activation of genes in the nucleus (2). The tempering of this 
signaling is mediated by receptor endocytosis, in which GAK plays central roles 
(as described in previous sections) (3). B. Action potentials are propagated along 
the axon (1) and terminate at the synapse. These potentials affect pre-positioned 
synaptic vesicles containing neurotransmitters, which are induced to release their 
contents into the synaptic cleft (2). After release, synaptic vesicles are reformed 
from the plasma membrane through the action of many synaptic proteins that 
mediate endocytosis (3), followed by the dissociation of clathrin from these 
vesicles by GAK and Hsc70 (4). Finally, the synaptic vesicles are reloaded with 
neurotransmitters (5) and are repositioned and primed for the next action 
potential. 
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Figure 21. Altered GAK Levels Cause Transcriptional Dysregulation and 
Synaptic Dysfunction in PD. A. Activation of trans-membrane receptor at the 
plasma membrane (1) leads to down-stream activation of signaling cascades. 
The receptor is not proper endocytosed after activation, as lowered GAK levels 
induce clathrin to be sequestered in the formed vesicles found in the cytoplasm 
(2). This causes aberrant cellular signaling, thus leading to transcriptional 
dysregulation (3). As SNCA is one gene which is increased in expression upon 
GAK reduction, this causes increased levels of the α-synuclein protein to be 
produced (4), which, when coupled with already present aggregates found in 
other neuronal parts, further potentiates the pathogenesis of disease. B. The 
action potential is propagated (1), but the number of poised synaptic vesicles is 
depleted, and so neurotransmitter release is blocked (2). This depletion of poised 
vesicles is due to the inability of the synapse to create new vesicles through 
endocytosis, as decreased GAK levels cause clathrin sequestration in very few 
vesicles (3). As a compensatory mechanism, the neuron initiates transcription of 
several genes responsible for synaptic vesicle formation (4), but the inability of 
Hsc70 to dissociate clathrin from these vesicles without GAK prevents this up-
regulation from restoring synaptic homeostasis.   
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 Using agnostic as well as genome-wide approaches, these studies 
enabled in depth investigation into a possible mechanism for the detriments 
associated with altered GAK expression, as well as the identification through 
pathway analysis of the altered genes of upstream regulators that might be 
targeted for therapeutic intervention. Future exploration into the genes and 
pathways implicated here using biochemical and pharmacological techniques will 
yield a greater understanding of the networks that are perturbed by GAK in 
Parkinson Disease and will provide novel areas for the advancement of PD 
treatments research.  
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